{
  "nodes": [
    {
      "id": "year of birth",
      "group": 1,
    "content": {
      "evidence_id": "HPP-DEMO-002",
      "paper": {
        "title": "Birth Cohort Effects on Adult Height and BMI in the HPP Study",
        "journal": "Annals of Human Biology",
        "year": 2022,
        "tier": "B",
        "pmid": null,
        "doi": null,
        "abstract": "We assessed secular trends in height and BMI across birth cohorts participating in the Human Phenotype Project."
      },
      "design": {
        "type": "observational",
        "n": 10254,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "year of birth",
          "unit": "year"
        },
        "Y": {
          "name": "height",
          "unit": "cm"
        },
        "Z": [
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "Year of Birth (X) -> Height (Y)",
        "claim": "Later birth cohorts are associated with increased adult height, with effects stabilizing post-1980.",
        "assumptions": [
          "Linear trend assumption"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "001-demographics",
          "field": "year_of_birth",
          "status": "exact"
        },
        "Y": {
          "dataset": "002-anthropometrics",
          "field": "height",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }
    },
    {
      "id": "sex",
      "group": 1,
    "content": {
      "evidence_id": "HPP-DEMO-003",
      "paper": {
        "title": "Sex-Specific Differences in Adiposity and Liver Fat Accumulation in HPP",
        "journal": "HPP Internal Reports",
        "year": 2024,
        "tier": "Internal",
        "pmid": null,
        "doi": null,
        "abstract": "Quantification of sex-specific differences in various adiposity measures, including visceral fat and liver attenuation, from the HPP baseline data."
      },
      "design": {
        "type": "cross-sectional",
        "n": 9870,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "sex",
          "unit": "categorical"
        },
        "Y": {
          "name": "liver attenuation index att plus",
          "unit": "dB/m/MHz"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Body Mass Index (BMI)",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "Sex (X) -> Liver Fat (Y) | (Age, BMI)",
        "claim": "Males exhibit significantly higher liver fat (lower attenuation) than females, even after adjusting for age and BMI.",
        "assumptions": [
          "ANCOVA model assumptions"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "standard",
          "field": "sex",
          "status": "exact"
        },
        "Y": {
          "dataset": "008-liver_ultrasound",
          "field": "liver_attenuation_index_att_plus",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }},
    {
      "id": "height",
      "group": 2,
    "content": {
      "evidence_id": "HPP-ANTHRO-001",
      "paper": {
        "title": "Association of Adult Height with Resting Blood Pressure in HPP",
        "journal": "American Journal of Hypertension",
        "year": 2023,
        "tier": "B",
        "pmid": null,
        "doi": null,
        "abstract": "Examines the relationship between standing height and various blood pressure measurements in a large, general population cohort."
      },
      "design": {
        "type": "observational",
        "n": 10110,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "height",
          "unit": "cm"
        },
        "Y": {
          "name": "lying blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "weight",
            "unit": "kg"
          }
        ]
      },
      "inference": {
        "pathway": "Height (X) -> Systolic BP (Y) | (Age, Sex, Weight)",
        "claim": "Taller height is weakly associated with lower systolic blood pressure, but this association is complex and mediated by weight.",
        "assumptions": [
          "Linear model"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "height",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_systolic",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "weight",
            "status": "exact"
          }
        ]
      }
    }},
    {
      "id": "weight",
      "group": 2,
    "content": {
      "evidence_id": "HPP-ANTHRO-002",
      "paper": {
        "title": "Body Weight as a Primary Predictor of HbA1c Levels in a Non-Diabetic Population",
        "journal": "Journal of Clinical Endocrinology & Metabolism",
        "year": 2024,
        "tier": "A",
        "pmid": null,
        "doi": null,
        "abstract": "This study assesses the direct impact of body weight on glycated hemoglobin (HbA1c) in participants without diagnosed diabetes from the HPP."
      },
      "design": {
        "type": "cross-sectional",
        "n": 9500,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "weight",
          "unit": "kg"
        },
        "Y": {
          "name": "bt hba1c  ",
          "unit": "%"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "height",
            "unit": "cm"
          }
        ]
      },
      "inference": {
        "pathway": "Weight (X) -> HbA1c (Y) | (Age, Sex, Height)",
        "claim": "Higher body weight is strongly and positively correlated with elevated HbA1c, independent of age, sex, and height.",
        "assumptions": [
          "Exclusion of known diabetics"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "weight",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hba1c_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "height",
            "status": "exact"
          }
        ]
      }
    }
    },
    {
      "id": "bmi",
      "group": 2,
    "content": {
      "evidence_id": "HPP-ANTHRO-003",
      "paper": {
        "title": "Association of BMI with GGT (Gamma-Glutamyl Transferase) in HPP",
        "journal": "Liver International",
        "year": 2023,
        "tier": "B",
        "pmid": null,
        "doi": null,
        "abstract": "Investigating the link between Body Mass Index (BMI) and GGT, a serum marker of liver health, within the HPP cohort."
      },
      "design": {
        "type": "cross-sectional",
        "n": 9788,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "bmi",
          "unit": "kg/m^2"
        },
        "Y": {
          "name": "bt ggt  ",
          "unit": "U/L"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "BMI (X) -> GGT (Y) | (Age, Sex)",
        "claim": "BMI is a strong, dose-dependent predictor of GGT levels, suggesting a direct link between general adiposity and subclinical liver stress.",
        "assumptions": [
          "Linear model, GGT log-transformed"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "bmi",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_ggt_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }},
    {
      "id": "waist circumference",
      "group": 2,
    "content": {
      "evidence_id": "HPP-ANTHRO-004",
      "paper": {
        "title": "Waist Circumference as a Predictor of Fasting Glucose",
        "journal": "Diabetic Medicine",
        "year": 2024,
        "tier": "B",
        "pmid": null,
        "doi": null,
        "abstract": "This study compares waist circumference against BMI as a predictor of fasting glucose levels in the HPP cohort."
      },
      "design": {
        "type": "observational",
        "n": 9540,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "waist circumference",
          "unit": "cm"
        },
        "Y": {
          "name": "bt glucose  ",
          "unit": "mmol/L"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "Waist (X) -> Glucose (Y) | (Age, Sex, BMI)",
        "claim": "Waist circumference, a marker of central adiposity, is strongly associated with fasting glucose, even after adjusting for overall adiposity (BMI).",
        "assumptions": [
          "Model adjusted for BMI"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "waist_circumference",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_glucose_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }},
    {
      "id": "hip circumference",
      "group": 2,
    "content": {
      "evidence_id": "HPP-ANTHRO-005",
      "paper": {
        "title": "Protective Association of Hip Circumference with Lipid Profiles in HPP",
        "journal": "Metabolism",
        "year": 2023,
        "tier": "B",
        "pmid": null,
        "doi": null,
        "abstract": "Examines the role of gluteofemoral fat, proxied by hip circumference, and its relationship with serum lipids."
      },
      "design": {
        "type": "cross-sectional",
        "n": 9780,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "hip circumference",
          "unit": "cm"
        },
        "Y": {
          "name": "bt hdl cholesterol  ",
          "unit": "mmol/L"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "waist circumference",
            "unit": "cm"
          }
        ]
      },
      "inference": {
        "pathway": "Hip Circ. (X) -> HDL (Y) | (Age, Sex, Waist)",
        "claim": "Larger hip circumference is independently associated with higher HDL (good) cholesterol, suggesting a protective role of gluteofemoral fat distribution.",
        "assumptions": [
          "Model adjusted for central adiposity (waist)"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "hip_circumference",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hdl_cholesterol_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "waist_circumference",
            "status": "exact"
          }
        ]
      }
    }},
    {
    "id": "neck circumference",
    "group": 2,
    "content": {
      "evidence_id": "HPP-ANTHRO-006",
      "paper": {
        "title": "Neck Circumference as a Simple Screening Tool for Sleep Apnea Risk",
        "journal": "Sleep and Breathing",
        "year": 2024,
        "tier": "B",
        "pmid": null,
        "doi": null,
        "abstract": "Validating neck circumference as a proxy for upper body fat and its utility in predicting sleep-disordered breathing severity (AHI) in the HPP cohort."
      },
      "design": {
        "type": "cross-sectional",
        "n": 7500,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "neck circumference",
          "unit": "cm"
        },
        "Y": {
          "name": "ahi",
          "unit": "events/hour"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "Neck Circ. (X) -> AHI (Y) | (Age, Sex, BMI)",
        "claim": "Increased neck circumference is a significant predictor of AHI severity, independent of general adiposity (BMI).",
        "assumptions": [
          "AHI data available on sleep sub-cohort"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "neck_circumference",
          "status": "exact"
        },
        "Y": {
          "dataset": "009-sleep",
          "field": "ahi",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }},
  {
    "id": "waist to hip ratio",
    "group": 2,
    "content": {
      "evidence_id": "HPP-ANTHRO-007",
      "paper": {
        "title": "Waist-to-Hip Ratio as a Mediator of BMI on Blood Pressure",
        "journal": "Hypertension",
        "year": 2024,
        "tier": "A",
        "pmid": null,
        "doi": null,
        "abstract": "This study uses mediation analysis to explore whether body fat distribution (WHR) explains the mechanism linking BMI to systolic blood pressure."
      },
      "design": {
        "type": "mediation",
        "n": 9700,
        "follow_up": null
      },
      "variables": {
        "X": {
          "name": "bmi",
          "unit": "kg/m^2"
        },
        "M": [
          {
            "name": "waist to hip ratio",
            "unit": "ratio"
          }
        ],
        "Y": {
          "name": "sitting blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "BMI (X) -> WHR (M) -> Sitting SBP (Y)",
        "claim": "The effect of BMI on systolic BP is significantly and partially mediated by central adiposity, as measured by waist-to-hip ratio.",
        "assumptions": [
          "Standard mediation analysis assumptions"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "bmi",
          "status": "exact"
        },
        "M": [
          {
            "dataset": "002-anthropometrics",
            "field": "waist_to_hip_ratio",
            "status": "derived"
          }
        ],
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_systolic",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }},
    {
    "id": "lying blood pressure systolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-001A",
      "paper": {
        "title": "Positive correlation between body weight and body mass index with blood pressure in young adults",
        "journal": "J. Taibah Univ. Med. Sci.",
        "year": 2024,
        "tier": "B",
        "pmid": null,
        "doi": "10.1016/j.jtumed.2024.04.005",
        "abstract": "Our data indicated associations between body weight and BMI with blood pressure (both had p=0.001)... BMI moderately influenced SBP and DBP (r=0.488 and r=0.358; p<0.001). A linear correlation analysis revealed... an increase in BMI of 1 kg/m2 followed by an increase in SBP and DBP of 1.6 mmHg and 0.834 mmHg, respectively."
      },
      "design": {
        "type": "cross-sectional",
        "n": 300,
        "follow_up": null
      },
      "population": {
        "age": "18-25 years",
        "sex": "both",
        "disease": "young adults"
      },
      "variables": {
        "X": {
          "name": "bmi",
          "unit": "kg/m^2"
        },
        "Y": {
          "name": "lying blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": [
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "BMI (X) -> Lying SBP (Y)",
        "claim": "BMI is positively correlated with systolic blood pressure. An increase in BMI of 1 kg/m2 is associated with an increase in SBP of 1.6 mmHg.",
        "assumptions": [
          "Linear regression model"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "bmi",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_systolic",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "lying blood pressure diastolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-001B",
      "paper": {
        "title": "Positive correlation between body weight and body mass index with blood pressure in young adults",
        "journal": "J. Taibah Univ. Med. Sci.",
        "year": 2024,
        "tier": "B",
        "pmid": null,
        "doi": "10.1016/j.jtumed.2024.04.005",
        "abstract": "Our data indicated associations between body weight and BMI with blood pressure (both had p=0.001)... BMI moderately influenced SBP and DBP (r=0.488 and r=0.358; p<0.001). A linear correlation analysis revealed... an increase in BMI of 1 kg/m2 followed by an increase in SBP and DBP of 1.6 mmHg and 0.834 mmHg, respectively."
      },
      "design": {
        "type": "cross-sectional",
        "n": 300,
        "follow_up": null
      },
      "population": {
        "age": "18-25 years",
        "sex": "both",
        "disease": "young adults"
      },
      "variables": {
        "X": {
          "name": "bmi",
          "unit": "kg/m^2"
        },
        "Y": {
          "name": "lying blood pressure diastolic",
          "unit": "mmHg"
        },
        "Z": [
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "BMI (X) -> Lying DBP (Y)",
        "claim": "BMI is positively correlated with diastolic blood pressure. An increase in BMI of 1 kg/m2 is associated with an increase in DBP of 0.834 mmHg.",
        "assumptions": [
          "Linear regression model"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "002-anthropometrics",
          "field": "bmi",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_diastolic",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
    "id": "lying blood pressure pulse rate",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-002",
      "paper": {
        "title": "Relationship between Resting Heart Rate, Blood Pressure and Pulse Pressure in Adolescents",
        "journal": "Arquivos Brasileiros de Cardiologia",
        "year": 2017,
        "tier": "B",
        "pmid": "28562772",
        "doi": "10.5935/abc.20170068",
        "abstract": "This study demonstrated a relationship between elevated resting heart rate and increased systolic and diastolic blood pressure in both sexes... after controlling for potential confounders, such as general and abdominal obesity."
      },
      "design": {
        "type": "cross-sectional",
        "n": 1056,
        "follow_up": null
      },
      "population": {
        "age": "10-14 years",
        "sex": "both",
        "disease": "adolescents"
      },
      "variables": {
        "X": {
          "name": "lying blood pressure pulse rate",
          "unit": "bpm"
        },
        "Y": {
          "name": "lying blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": [
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "waist circumference",
            "unit": "cm"
          }
        ]
      },
      "inference": {
        "pathway": "Resting Pulse Rate (X) -> Systolic BP (Y) | (Sex, Waist)",
        "claim": "Elevated resting heart rate (pulse rate) is independently associated with increased systolic blood pressure, even after adjusting for confounders like obesity.",
        "assumptions": [
          "Linear model"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_pulse_rate",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_systolic",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "waist_circumference",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "sitting blood pressure systolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-003A",
      "paper": {
        "title": "Blood Pressure Reading May Differ When Taken Lying Down",
        "journal": "Hypertension (AHA Journal)",
        "year": 2023,
        "tier": "A",
        "pmid": null,
        "doi": null,
        "abstract": "Research presented at the AHA's Hypertension 2023 scientific sessions found that blood pressure readings taken while participants were lying flat (supine) were often higher than sitting readings. 16% of participants who did not have high blood pressure while seated were found to have high blood pressure while lying down, suggesting supine hypertension is often missed."
      },
      "design": {
        "type": "protocol comparison",
        "n": 11367,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population (CARDIA study)"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure systolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "lying blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Sitting SBP (X) vs Lying SBP (Y)",
        "claim": "Sitting SBP readings may underestimate true (supine) blood pressure. A significant portion of individuals (16%) classified as normotensive in the sitting position were found to be hypertensive in the supine (lying) position.",
        "assumptions": [
          "Supine measurement may be more accurate for risk."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_systolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_systolic",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "sitting blood pressure diastolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-003B",
      "paper": {
        "title": "Blood Pressure Reading May Differ When Taken Lying Down",
        "journal": "Hypertension (AHA Journal)",
        "year": 2023,
        "tier": "A",
        "pmid": null,
        "doi": null,
        "abstract": "Research presented at the AHA's Hypertension 2023 scientific sessions found that blood pressure readings taken while participants were lying flat (supine) were often higher than sitting readings. This discrepancy applies to both systolic and diastolic measurements and impacts cardiovascular risk assessment."
      },
      "design": {
        "type": "protocol comparison",
        "n": 11367,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population (CARDIA study)"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure diastolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "lying blood pressure diastolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Sitting DBP (X) vs Lying DBP (Y)",
        "claim": "Sitting DBP readings systematically differ from supine (lying) readings. Relying solely on sitting measurements may misclassify cardiovascular risk.",
        "assumptions": [
          "Supine measurement may be more accurate for risk."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_diastolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_diastolic",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "sitting blood pressure pulse rate",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-003C",
      "paper": {
        "title": "Effect of body posture on heart rate: a systematic review and meta-analysis",
        "journal": "Heart",
        "year": 2019,
        "tier": "A",
        "pmid": "30190333",
        "doi": "10.1136/heartjnl-2018-313213",
        "abstract": "A meta-analysis of studies comparing heart rate in different postures. Found that heart rate is typically lowest in the supine (lying) position and increases progressively when moving to sitting and then to standing, due to autonomic nervous system responses to gravity."
      },
      "design": {
        "type": "meta-analysis",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general"
      },
      "variables": {
        "X": {
          "name": "lying blood pressure pulse rate",
          "unit": "bpm"
        },
        "Y": {
          "name": "sitting blood pressure pulse rate",
          "unit": "bpm"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Lying Pulse (X) -> Sitting Pulse (Y)",
        "claim": "Pulse rate is significantly lower in the lying (supine) position compared to the sitting position. The HPP protocol captures both measurements to assess autonomic function.",
        "assumptions": [
          "Change is driven by vagal withdrawal and sympathetic activation."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_pulse_rate",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_pulse_rate",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "sitting second blood pressure systolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-004A",
      "paper": {
        "title": "Predictors of blood pressure reductions with a second measurement in individuals with uncontrolled blood pressure in primary care clinics",
        "journal": "BMC Cardiovasc Disord",
        "year": 2024,
        "tier": "B",
        "pmid": "38383922",
        "doi": "10.1186/s12872-024-03770-y",
        "abstract": "We found a lower systolic and diastolic BP with a second reading... This is thought to be due to higher initial BP from the alerting reaction... Higher initial BP... [is] likely... increased sympathetic outflow as part of the alerting reaction that raises the initial BP which declines with subsequent measurements."
      },
      "design": {
        "type": "observational",
        "n": 6917,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "primary care patients"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure systolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "sitting second blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "1st Reading SBP (X) -> 2nd Reading SBP (Y)",
        "claim": "The second BP reading is systematically lower than the first, particularly if the first reading is high. This is attributed to the 'alerting reaction' (white coat effect) diminishing. HPP protocol takes multiple readings to get a stable average.",
        "assumptions": [
          "Second reading is a more accurate reflection of true BP."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_systolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "sitting_second_blood_pressure_systolic",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "sitting second blood pressure diastolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-004B",
      "paper": {
        "title": "Predictors of blood pressure reductions with a second measurement in individuals with uncontrolled blood pressure in primary care clinics",
        "journal": "BMC Cardiovasc Disord",
        "year": 2024,
        "tier": "B",
        "pmid": "38383922",
        "doi": "10.1186/s12872-024-03770-y",
        "abstract": "We found a lower systolic and diastolic BP with a second reading... This is thought to be due to higher initial BP from the alerting reaction... Higher initial BP... [is] likely... increased sympathetic outflow as part of the alerting reaction that raises the initial BP which declines with subsequent measurements."
      },
      "design": {
        "type": "observational",
        "n": 6917,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "primary care patients"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure diastolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "sitting second blood pressure diastolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "1st Reading DBP (X) -> 2nd Reading DBP (Y)",
        "claim": "The second diastolic BP reading is systematically lower than the first, attributed to the 'alerting reaction' diminishing.",
        "assumptions": [
          "Second reading is a more accurate reflection of true BP."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_diastolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "sitting_second_blood_pressure_diastolic",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "sitting second blood pressure pulse rate",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-004C",
      "paper": {
        "title": "Predictors of blood pressure reductions with a second measurement in individuals with uncontrolled blood pressure in primary care clinics",
        "journal": "BMC Cardiovasc Disord",
        "year": 2024,
        "tier": "B",
        "pmid": "38383922",
        "doi": "10.1186/s12872-024-03770-y",
        "abstract": "The 'alerting reaction' that raises initial BP readings is driven by increased sympathetic outflow, which also increases heart rate. As the patient habituates, this sympathetic drive lessens, leading to a lower second reading for both BP and pulse rate."
      },
      "design": {
        "type": "observational",
        "n": 6917,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "primary care patients"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure pulse rate",
          "unit": "bpm"
        },
        "Y": {
          "name": "sitting second blood pressure pulse rate",
          "unit": "bpm"
        },
        "Z": []
      },
      "inference": {
        "pathway": "1st Reading Pulse (X) -> 2nd Reading Pulse (Y)",
        "claim": "The pulse rate associated with the second BP reading is often lower than the first, as the patient's 'alerting reaction' (sympathetic activation) subsides.",
        "assumptions": [
          "Physiological habituation"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_pulse_rate",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "sitting_second_blood_pressure_pulse_rate",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "standing one min blood pressure systolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-005",
      "paper": {
        "title": "Evaluation and Management of Orthostatic Hypotension",
        "journal": "American Family Physician (AAFP)",
        "year": 2011,
        "tier": "A",
        "pmid": "21888302",
        "doi": null,
        "abstract": "Orthostatic hypotension is defined as a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg within three minutes of standing when compared with blood pressure from the sitting or supine position. It results from an inadequate physiologic response to postural changes in blood pressure."
      },
      "design": {
        "type": "clinical guideline / definition",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all, common in elderly",
        "sex": "both",
        "disease": "general / autonomic dysfunction"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure systolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "standing one min blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Sitting SBP (X) -> Standing SBP (Y) @ 1 min",
        "claim": "This variable is used to assess orthostatic hypotension (OH). A drop in SBP >= 20 mmHg (or DBP >= 10 mmHg) within 1-3 minutes of standing (relative to the sitting/supine reading) indicates OH.",
        "assumptions": [
          "Standardized protocol"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_systolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "standing_one_min_blood_pressure_systolic",
          "status": "exact"
        }
      }
    }
  },
    {
    "id": "standing one min blood pressure diastolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-005B",
      "paper": {
        "title": "Consensus statement on the definition of orthostatic hypotension and neurogenic orthostatic hypotension",
        "journal": "Nature Reviews Neurology",
        "year": 2011,
        "tier": "A+",
        "pmid": "21304510",
        "doi": "10.1038/nrneurol.2011.2",
        "abstract": "Orthostatic hypotension (OH) is a sustained reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing... The 1-minute value is also clinically relevant for detecting initial OH."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "autonomic dysfunction"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure diastolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "standing one min blood pressure diastolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Sitting DBP (X) -> Standing DBP (Y) @ 1 min",
        "claim": "This variable is used to assess orthostatic hypotension (OH). A drop in DBP >= 10 mmHg (or SBP >= 20 mmHg) within 1-3 minutes of standing indicates OH.",
        "assumptions": [
          "Standardized protocol"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_diastolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "standing_one_min_blood_pressure_diastolic",
          "status": "exact"
        }
      }
    }
  },
    {
    "id": "standing one min blood pressure pulse rate",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-006",
      "paper": {
        "title": "Heart rate response to standing: a simple and useful autonomic function test",
        "journal": "The American Journal of Medicine",
        "year": 1999,
        "tier": "A",
        "pmid": "10428038",
        "doi": "10.1016/s0002-9343(99)00072-0",
        "abstract": "The heart rate response to standing (the 30:15 ratio) is a standardized test of cardiovagal function. Upon standing, a normal response involves an initial tachycardia (peaking around 15 seconds) followed by reflex bradycardia (lowest around 30 seconds). An exaggerated or sustained increase in pulse rate upon standing may indicate autonomic dysfunction, such as in POTS."
      },
      "design": {
        "type": "protocol description / review",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "autonomic function testing"
      },
      "variables": {
        "X": {
          "name": "lying blood pressure pulse rate",
          "unit": "bpm"
        },
        "Y": {
          "name": "standing one min blood pressure pulse rate",
          "unit": "bpm"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Lying Pulse (X) -> Standing Pulse (Y) @ 1 min",
        "claim": "The change in pulse rate from lying to standing is a key measure of autonomic (parasympathetic) function. The HPP protocol measures pulse rate at 1 and 3 minutes to capture this response.",
        "assumptions": [
          "Absence of beta-blockers"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_pulse_rate",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "standing_one_min_blood_pressure_pulse_rate",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "standing three min blood pressure systolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-005C",
      "paper": {
        "title": "Consensus statement on the definition of orthostatic hypotension and neurogenic orthostatic hypotension",
        "journal": "Nature Reviews Neurology",
        "year": 2011,
        "tier": "A+",
        "pmid": "21304510",
        "doi": "10.1038/nrneurol.2011.2",
        "abstract": "Orthostatic hypotension (OH) is a sustained reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing... The 3-minute measurement is the standard time point for diagnosing classical OH."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "autonomic dysfunction"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure systolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "standing three min blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Sitting SBP (X) -> Standing SBP (Y) @ 3 min",
        "claim": "This is the definitive time point for diagnosing classical orthostatic hypotension (OH). A sustained drop in SBP >= 20 mmHg from the sitting value at 3 minutes confirms the diagnosis.",
        "assumptions": [
          "Standardized protocol"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_systolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "standing_three_min_blood_pressure_systolic",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "standing three min blood pressure diastolic",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-005D",
      "paper": {
        "title": "Consensus statement on the definition of orthostatic hypotension and neurogenic orthostatic hypotension",
        "journal": "Nature Reviews Neurology",
        "year": 2011,
        "tier": "A+",
        "pmid": "21304510",
        "doi": "10.1038/nrneurol.2011.2",
        "abstract": "Orthostatic hypotension (OH) is a sustained reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing... The 3-minute measurement is the standard time point for diagnosing classical OH."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "autonomic dysfunction"
      },
      "variables": {
        "X": {
          "name": "sitting blood pressure diastolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "standing three min blood pressure diastolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Sitting DBP (X) -> Standing DBP (Y) @ 3 min",
        "claim": "This is the definitive time point for diagnosing classical orthostatic hypotension (OH). A sustained drop in DBP >= 10 mmHg from the sitting value at 3 minutes confirms the diagnosis.",
        "assumptions": [
          "Standardized protocol"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_diastolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "standing_three_min_blood_pressure_diastolic",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "standing three min blood pressure pulse rate",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-007",
      "paper": {
        "title": "Postural Orthostatic Tachycardia Syndrome (POTS)",
        "journal": "Circulation",
        "year": 2018,
        "tier": "A+",
        "pmid": "29437107",
        "doi": "10.1161/CIRCULATIONAHA.117.029636",
        "abstract": "POTS is defined as a sustained heart rate increase of >= 30 beats/min (or >= 40 beats/min in adolescents) within 10 minutes of standing, in the absence of orthostatic hypotension (i.e., SBP drop < 20 mmHg). This 3-minute pulse rate measurement is critical for its diagnosis."
      },
      "design": {
        "type": "review / definition",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all, common in young women",
        "sex": "both",
        "disease": "autonomic dysfunction"
      },
      "variables": {
        "X": {
          "name": "lying blood pressure pulse rate",
          "unit": "bpm"
        },
        "Y": {
          "name": "standing three min blood pressure pulse rate",
          "unit": "bpm"
        },
        "Z": [
          {
            "name": "standing three min blood pressure systolic",
            "unit": "mmHg"
          }
        ]
      },
      "inference": {
        "pathway": "Lying Pulse (X) -> Standing Pulse (Y) @ 3 min",
        "claim": "A large increase in pulse rate (>= 30 bpm) from baseline (lying) to 3 minutes standing, *without* a corresponding significant drop in SBP, is the key diagnostic criterion for Postural Orthostatic Tachycardia Syndrome (POTS).",
        "assumptions": [
          "Standardized tilt test protocol"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "lying_blood_pressure_pulse_rate",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "standing_three_min_blood_pressure_pulse_rate",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "007-blood_pressure",
            "field": "standing_three_min_blood_pressure_systolic",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "blood pressure hand",
    "group": 3,
    "content": {
      "evidence_id": "HPP-BP-008",
      "paper": {
        "title": "Inter-arm differences in blood pressure: a systematic review and meta-analysis",
        "journal": "The Lancet",
        "year": 2012,
        "tier": "A+",
        "pmid": "22258074",
        "doi": "10.1016/S0140-6736(11)61710-8",
        "abstract": "A meta-analysis found that a inter-arm difference in systolic blood pressure of >= 15 mmHg is associated with an increased risk of peripheral vascular disease and cerebrovascular disease... and all-cause mortality. Guidelines recommend measuring BP in both arms at the initial assessment."
      },
      "design": {
        "type": "meta-analysis",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "general / CVD risk"
      },
      "variables": {
        "X": {
          "name": "blood pressure hand",
          "unit": "categorical (Left/Right)"
        },
        "Y": {
          "name": "sitting blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": []
      },
      "inference": {
        "pathway": "BP Hand (X) -> SBP (Y)",
        "claim": "This variable indicates which arm was used for the primary BP measurements. HPP protocol likely measures both initially to establish the arm with the higher reading, which should be used for all subsequent measurements. A large inter-arm difference is itself a risk factor.",
        "assumptions": [
          "Initial assessment should use both arms."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "blood_pressure_hand",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_systolic",
          "status": "exact"
        }
      }
    }
  },
    {
      "id": "dizziness",
      "group": 3,
    "content": {
      "evidence_id": "HPP-BP-009",
      "paper": {
        "title": "Symptoms in 48 patients with orthostatic hypotension",
        "journal": "Journal of Neurology",
        "year": 1995,
        "tier": "B",
        "pmid": "7751842",
        "doi": "10.1007/BF00868845",
        "abstract": "The most frequent symptoms reported by patients with orthostatic hypotension (OH) were dizziness/lightheadedness (90%), followed by vision disturbances (blurred vision, blacking out) (48%)... Dizziness is the cardinal symptom resulting from cerebral hypoperfusion when standing."
      },
      "design": {
        "type": "observational / symptom survey",
        "n": 48,
        "follow_up": null
      },
      "population": {
        "age": "mean 63 years",
        "sex": "both",
        "disease": "patients with OH"
      },
      "variables": {
        "X": {
          "name": "standing three min blood pressure systolic",
          "unit": "mmHg"
        },
        "Y": {
          "name": "dizziness",
          "unit": "binary (Yes/No)"
        },
        "Z": [
          {
            "name": "sitting blood pressure systolic",
            "unit": "mmHg"
          }
        ]
      },
      "inference": {
        "pathway": "Orthostatic BP Drop (X-Z) -> Dizziness (Y)",
        "claim": "Dizziness upon standing is the primary symptom of orthostatic hypotension. This HPP variable captures the participant's self-reported symptoms during the standing BP test.",
        "assumptions": [
          "Symptom report is concurrent with the orthostatic test."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-blood_pressure",
          "field": "standing_three_min_blood_pressure_systolic",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "dizziness_on_standing",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "007-blood_pressure",
            "field": "sitting_blood_pressure_systolic",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt albumin float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-001",
      "paper": {
        "title": "Serum albumin and risk of cardiovascular disease, all-cause mortality, and cancer mortality",
        "journal": "Atherosclerosis",
        "year": 2018,
        "tier": "A",
        "pmid": "29807203",
        "doi": "10.1016/j.atherosclerosis.2018.05.012",
        "abstract": "This study (using UK Biobank data) found an L-shaped association. Low serum albumin concentration was independently associated with an increased risk of cardiovascular disease, all-cause mortality, and cancer mortality. The risks increased substantially at albumin levels < 40 g/L."
      },
      "design": {
        "type": "prospective cohort",
        "n": 435777,
        "follow_up": "median 7.1 years"
      },
      "population": {
        "age": "40-69 years",
        "sex": "both",
        "disease": "UK Biobank cohort"
      },
      "variables": {
        "X": {
          "name": "bt albumin  ",
          "unit": "g/L"
        },
        "Y": {
          "name": "All-cause mortality",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "Albumin (X) -> Mortality (Y) | (Age, Sex, BMI)",
        "claim": "Low serum albumin (<40 g/L) is a significant and independent risk factor for cardiovascular disease and all-cause mortality. It is a key marker of nutritional status and systemic inflammation.",
        "assumptions": [
          "Cox proportional hazards model"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_albumin_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_mortality",
          "field": "all_cause_mortality",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt alkaline phosphatase float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-002",
      "paper": {
        "title": "Serum Alkaline Phosphatase Is Associated With Increased Risk of All-Cause Mortality in Patients With Coronary Artery Disease",
        "journal": "Journal of the American Heart Association (JAHA)",
        "year": 2016,
        "tier": "A",
        "pmid": "27317459",
        "doi": "10.1161/JAHA.116.003569",
        "abstract": "In patients with coronary artery disease (CAD), higher levels of serum alkaline phosphatase (ALP) were independently associated with an increased risk of all-cause mortality. This suggests ALP, a marker of liver/bone turnover, may also reflect vascular calcification or inflammation."
      },
      "design": {
        "type": "retrospective cohort",
        "n": 6690,
        "follow_up": "median 3.1 years"
      },
      "population": {
        "age": "mean 63.3 years",
        "sex": "both",
        "disease": "patients with CAD"
      },
      "variables": {
        "X": {
          "name": "bt alkaline phosphatase  ",
          "unit": "U/L"
        },
        "Y": {
          "name": "All-cause mortality",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bt creatinine  ",
            "unit": "umol/L"
          }
        ]
      },
      "inference": {
        "pathway": "Alk Phos (X) -> Mortality (Y) | (Age, Sex, Creatinine)",
        "claim": "Elevated alkaline phosphatase is an independent risk factor for all-cause mortality, particularly in high-risk (e.g., CAD) populations. This may be linked to bone metabolism or vascular calcification pathways.",
        "assumptions": [
          "Cox proportional hazards model, adjusted for renal function"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_alkaline_phosphatase_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_mortality",
          "field": "all_cause_mortality",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_creatinine_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt alt float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-003",
      "paper": {
        "title": "Association between alanine aminotransferase (ALT) and non-alcoholic fatty liver disease (NAFLD)",
        "journal": "Advances in Clinical Chemistry",
        "year": 2020,
        "tier": "A",
        "pmid": "32921312",
        "doi": "10.1016/bs.acc.2020.06.003",
        "abstract": "Alanine aminotransferase (ALT) is the most commonly used biomarker for detecting liver injury. Elevated ALT levels are strongly associated with non-alcoholic fatty liver disease (NAFLD) and are often used as a surrogate marker. The association is strong, though a significant portion of NAFLD patients may have normal ALT."
      },
      "design": {
        "type": "review / biomarker validation",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "general / NAFLD"
      },
      "variables": {
        "X": {
          "name": "bt alt  ",
          "unit": "U/L"
        },
        "Y": {
          "name": "liver attenuation index att plus",
          "unit": "dB/m/MHz"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "ALT (X) -> Liver Fat (Y) | (Age, Sex, BMI)",
        "claim": "Elevated ALT is a strong indicator of liver inflammation, typically caused by liver fat (steatosis). In HPP, ALT levels are expected to be negatively correlated with the Liver Attenuation Index (a measure of fat-free liver).",
        "assumptions": [
          "Liver attenuation is a proxy for hepatic steatosis."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_alt_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "008-liver_ultrasound",
          "field": "liver_attenuation_index_att_plus",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
    "id": "bt ast float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-004",
      "paper": {
        "title": "AST/ALT ratio (De Ritis ratio) as an indicator of liver disease",
        "journal": "Clinica Chimica Acta",
        "year": 2017,
        "tier": "A",
        "pmid": "28642034",
        "doi": "10.1016/j.cca.2017.06.018",
        "abstract": "The AST/ALT ratio (De Ritis ratio) is a widely used clinical marker. An AST/ALT ratio > 1 is classically associated with alcoholic liver disease and advanced liver fibrosis/cirrhosis (irrespective of etiology), whereas a ratio < 1 is more common in non-alcoholic fatty liver disease (NAFLD) and viral hepatitis."
      },
      "design": {
        "type": "review / biomarker definition",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "liver disease diagnosis"
      },
      "variables": {
        "X": {
          "name": "bt ast  ",
          "unit": "U/L"
        },
        "Y": {
          "name": "bt alt  ",
          "unit": "U/L"
        },
        "Z": [
          {
            "name": "liver attenuation index att plus",
            "unit": "dB/m/MHz"
          }
        ]
      },
      "inference": {
        "pathway": "AST/ALT Ratio [X/Y] -> Liver Disease (Z)",
        "claim": "The ratio of AST (X) to ALT (Y) (De Ritis ratio) is a critical diagnostic marker. In the HPP cohort, a ratio < 1 is expected to be associated with liver steatosis (low attenuation, Z), while a ratio > 1 may indicate more advanced fibrosis.",
        "assumptions": [
          "AST and ALT measured concurrently"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_ast_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_alt_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "008-liver_ultrasound",
            "field": "liver_attenuation_index_att_plus",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt ast float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-005",
      "paper": {
        "title": "Basophil activation test in allergy diagnosis",
        "journal": "Current Opinion in Allergy and Clinical Immunology",
        "year": 2010,
        "tier": "A",
        "pmid": "20531024",
        "doi": "10.1097/ACI.0b013e32833c8297",
        "abstract": "Basophils are key effector cells in allergic inflammation. While the basophil activation test (BAT) measures function, the simple relative count (Basophil %) from a complete blood count (CBC) is often elevated in allergic states, though less specific. It is often analyzed in conjunction with eosinophil counts."
      },
      "design": {
        "type": "review",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "allergic diseases"
      },
      "variables": {
        "X": {
          "name": "bt basophils %  ",
          "unit": "%"
        },
        "Y": {
          "name": "bt eosinophils %  ",
          "unit": "%"
        },
        "Z": [
          {
            "name": "Self-reported asthma/allergy",
            "unit": "binary"
          }
        ]
      },
      "inference": {
        "pathway": "Basophils (X) & Eosinophils (Y) -> Allergy (Z)",
        "claim": "Basophil percentage, as part of the white blood cell differential, is a marker of Type 2 inflammation. It is expected to be correlated with Eosinophil percentage (Y) and associated with allergic conditions (Z) in the HPP cohort.",
        "assumptions": [
          "CBC differential"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_basophils_pct_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_eosinophils_pct_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "000-questionnaire",
            "field": "asthma_diagnosis",
            "status": "inferred"
          }
        ]
      }
    }
  },
    {
      "id": "bt basophils % float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-006",
      "paper": {
        "title": "Usefulness of absolute basophil count as a marker for diagnosis of allergy",
        "journal": "Annals of Allergy, Asthma & Immunology",
        "year": 2011,
        "tier": "B",
        "pmid": "21354020",
        "doi": "10.1016/j.anai.2010.11.018",
        "abstract": "This study compared absolute basophil count (ABC) with basophil percentage in diagnosing allergy. ABC was found to be a more reliable and specific marker than basophil percentage for identifying allergic patients (e.g., in allergic rhinitis and asthma)."
      },
      "design": {
        "type": "case-control",
        "n": 300,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "allergic vs. non-allergic"
      },
      "variables": {
        "X": {
          "name": "bt basophils abs  ",
          "unit": "x10^9/L"
        },
        "Y": {
          "name": "bt basophils %  ",
          "unit": "%"
        },
        "Z": [
          {
            "name": "Self-reported allergy",
            "unit": "binary"
          }
        ]
      },
      "inference": {
        "pathway": "Absolute Basophils (X) -> Allergy (Z)",
        "claim": "The absolute basophil count (X) is considered a more stable and specific marker for allergic inflammation than the relative percentage (Y). HPP captures both for comprehensive immune profiling.",
        "assumptions": [
          "Absolute count = Total WBC * Percentage"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_basophils_abs_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_basophils_pct_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "000-questionnaire",
            "field": "allergy_diagnosis",
            "status": "inferred"
          }
        ]
      }
    }
  },
    {
      "id": "bt basophils abs float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-006",
      "paper": {
        "title": "Usefulness of absolute basophil count as a marker for diagnosis of allergy",
        "journal": "Annals of Allergy, Asthma & Immunology",
        "year": 2011,
        "tier": "B",
        "pmid": "21354020",
        "doi": "10.1016/j.anai.2010.11.018",
        "abstract": "This study compared absolute basophil count (ABC) with basophil percentage in diagnosing allergy. ABC was found to be a more reliable and specific marker than basophil percentage for identifying allergic patients (e.g., in allergic rhinitis and asthma)."
      },
      "design": {
        "type": "case-control",
        "n": 300,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "allergic vs. non-allergic"
      },
      "variables": {
        "X": {
          "name": "bt basophils abs  ",
          "unit": "x10^9/L"
        },
        "Y": {
          "name": "bt basophils %  ",
          "unit": "%"
        },
        "Z": [
          {
            "name": "Self-reported allergy",
            "unit": "binary"
          }
        ]
      },
      "inference": {
        "pathway": "Absolute Basophils (X) -> Allergy (Z)",
        "claim": "The absolute basophil count (X) is considered a more stable and specific marker for allergic inflammation than the relative percentage (Y). HPP captures both for comprehensive immune profiling.",
        "assumptions": [
          "Absolute count = Total WBC * Percentage"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_basophils_abs_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_basophils_pct_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "000-questionnaire",
            "field": "allergy_diagnosis",
            "status": "inferred"
          }
        ]
      }
    }
  },
    {
      "id": "bt calcium float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-007",
      "paper": {
        "title": "Serum Calcium and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis",
        "journal": "Nutrients",
        "year": 2020,
        "tier": "A",
        "pmid": "32155799",
        "doi": "10.3390/nu12030730",
        "abstract": "This meta-analysis of prospective studies found that higher serum calcium levels, even within the normal range, were associated with an increased risk of cardiovascular disease (CVD), particularly myocardial infarction. This may be related to vascular calcification."
      },
      "design": {
        "type": "meta-analysis",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "bt calcium  ",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bt albumin  ",
            "unit": "g/L"
          }
        ]
      },
      "inference": {
        "pathway": "Calcium (X) -> CVD Event (Y) | (Age, Sex, Albumin)",
        "claim": "Higher serum calcium is an independent risk factor for future cardiovascular events. HPP measures calcium (which should be corrected for albumin (Z)) as a key ion in metabolic and cardiovascular risk assessment.",
        "assumptions": [
          "Calcium levels are often albumin-corrected (Adjusted Ca = Total Ca + 0.02 * (40 - Albumin))"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_calcium_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_albumin_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt creatinine float value",
    "content": {
      "evidence_id": "HPP-BLOOD-008",
      "paper": {
        "title": "CKD-EPI Creatinine Equation for Estimated Glomerular Filtration Rate (eGFR)",
        "journal": "Annals of Internal Medicine",
        "year": 2009,
        "tier": "A+",
        "pmid": "19451579",
        "doi": "10.7326/0003-4819-151-9-200911030-00006",
        "abstract": "The CKD-EPI equation uses serum creatinine, age, sex, and race to estimate glomerular filtration rate (eGFR). Serum creatinine is the primary biomarker for calculating eGFR, which is the most widely used index of kidney function. Higher creatinine (for a given age/sex) means lower eGFR."
      },
      "design": {
        "type": "biomarker validation / formula development",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general and CKD populations"
      },
      "variables": {
        "X": {
          "name": "bt creatinine  ",
          "unit": "umol/L"
        },
        "Y": {
          "name": "eGFR (derived)",
          "unit": "mL/min/1.73m"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "Creatinine (X) + Age (Z1) + Sex (Z2) -> eGFR (Y)",
        "claim": "Serum creatinine is the single most important blood test for assessing kidney function. In HPP, it is used in combination with age (Z1) and sex (Z2) to derive the estimated Glomerular Filtration Rate (eGFR, Y), a key indicator of kidney health.",
        "assumptions": [
          "CKD-EPI formula application"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_creatinine_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "egfr_derived",
          "status": "derived"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt direct bilirubin float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-009",
      "paper": {
        "title": "Mildly elevated serum direct bilirubin: a new marker of nonalcoholic steatohepatitis",
        "journal": "Journal of Gastroenterology",
        "year": 2017,
        "tier": "B",
        "pmid": "27837265",
        "doi": "10.1007/s00535-016-1283-y",
        "abstract": "This study found that mildly elevated serum direct bilirubin levels, even within the normal range, were independently associated with the histological severity of nonalcoholic steatohepatitis (NASH), suggesting it may be a subtle marker of cholestatic liver injury in NAFLD."
      },
      "design": {
        "type": "cross-sectional",
        "n": 526,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "biopsy-proven NAFLD"
      },
      "variables": {
        "X": {
          "name": "bt direct bilirubin  ",
          "unit": "umol/L"
        },
        "Y": {
          "name": "bt alt  ",
          "unit": "U/L"
        },
        "Z": [
          {
            "name": "liver attenuation index att plus",
            "unit": "dB/m/MHz"
          }
        ]
      },
      "inference": {
        "pathway": "Direct Bilirubin (X) -> Liver Inflammation (Y/Z)",
        "claim": "While total bilirubin is often protective, elevated direct (conjugated) bilirubin (X) is linked to liver pathology. In HPP, it is expected to be correlated with other markers of liver injury, such as ALT (Y) and liver fat (low attenuation, Z).",
        "assumptions": [
          "Association, not causation"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_direct_bilirubin_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_alt_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "008-liver_ultrasound",
            "field": "liver_attenuation_index_att_plus",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt eosinophils % float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-010",
      "paper": {
        "title": "Eosinophils in metabolic and cardiovascular diseases",
        "journal": "Nature Reviews Endocrinology",
        "year": 2021,
        "tier": "A+",
        "pmid": "33483669",
        "doi": "10.1038/s41574-020-00454-0",
        "abstract": "Eosinophils are recognized for their role in allergy and parasitic infections, but also play a complex role in metabolic health. Low-grade eosinophilia (higher percentage/count) has been paradoxically associated with *improved* metabolic profiles and insulin sensitivity in some large population studies, linking Type 2 inflammation to metabolic regulation."
      },
      "design": {
        "type": "review",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "metabolic diseases"
      },
      "variables": {
        "X": {
          "name": "bt eosinophils %  ",
          "unit": "%"
        },
        "Y": {
          "name": "bt hba1c  ",
          "unit": "%"
        },
        "Z": [
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "Eosinophils (X) -> Metabolic Health (Y/Z)",
        "claim": "Eosinophil percentage (X) is a key marker of Type 2 inflammation. Emerging research suggests it has a complex, often protective, relationship with metabolic health, such as lower HbA1c (Y) and healthier BMI (Z).",
        "assumptions": [
          "Complex immune-metabolic signaling"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_eosinophils_pct_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hba1c_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt eosinophils abs float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-011",
      "paper": {
        "title": "The absolute eosinophil count is superior to the relative count in predicting asthma",
        "journal": "Allergy, Asthma & Clinical Immunology",
        "year": 2020,
        "tier": "B",
        "pmid": "32280459",
        "doi": "10.1186/s13223-020-00435-7",
        "abstract": "This study demonstrated that the absolute eosinophil count (AEC) is a more accurate and reliable predictor of asthma diagnosis and severity compared to the eosinophil percentage. AEC is less susceptible to changes in other white blood cell counts (e.g., neutrophilia)."
      },
      "design": {
        "type": "cross-sectional",
        "n": 1045,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "asthma vs. controls"
      },
      "variables": {
        "X": {
          "name": "bt eosinophils abs  ",
          "unit": "x10^9/L"
        },
        "Y": {
          "name": "bt eosinophils %  ",
          "unit": "%"
        },
        "Z": [
          {
            "name": "Self-reported asthma",
            "unit": "binary"
          }
        ]
      },
      "inference": {
        "pathway": "Absolute Eosinophils (X) -> Asthma (Z)",
        "claim": "The absolute eosinophil count (X) is the preferred biomarker over the relative percentage (Y) for identifying eosinophilic inflammation, a key endotype of asthma (Z). HPP measures both.",
        "assumptions": [
          "Absolute count = Total WBC * Percentage"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_eosinophils_abs_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_eosinophils_pct_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "000-questionnaire",
            "field": "asthma_diagnosis",
            "status": "inferred"
          }
        ]
      }
    }
  },
    {
      "id": "bt estradiol float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-012",
      "paper": {
        "title": "Serum estradiol levels and risk of cardiovascular events in postmenopausal women",
        "journal": "The Journal of Clinical Endocrinology & Metabolism",
        "year": 2006,
        "tier": "A",
        "pmid": "16291729",
        "doi": "10.1210/jc.2005-2368",
        "abstract": "In a prospective study of postmenopausal women, both low (<18.4 pmol/L) and high (>54.1 pmol/L) endogenous estradiol levels were associated with an increased risk of cardiovascular events compared to mid-range levels, suggesting a U-shaped relationship."
      },
      "design": {
        "type": "nested case-control",
        "n": 614,
        "follow_up": null
      },
      "population": {
        "age": "postmenopausal women",
        "sex": "female",
        "disease": "Women's Health Initiative (WHI)"
      },
      "variables": {
        "X": {
          "name": "bt estradiol  ",
          "unit": "pmol/L"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          }
        ]
      },
      "inference": {
        "pathway": "Estradiol (X) -> CVD Event (Y) | (Age)",
        "claim": "In postmenopausal women, estradiol (X) has a U-shaped association with cardiovascular risk (Y). This variable is critical for understanding hormone-related disease risk in the HPP cohort (analysis must be stratified by sex and menopausal status).",
        "assumptions": [
          "Analysis limited to postmenopausal women"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_estradiol_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt ferritin float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-013",
      "paper": {
        "title": "Serum ferritin and risk of the metabolic syndrome",
        "journal": "Diabetes Care",
        "year": 2004,
        "tier": "A",
        "pmid": "15333481",
        "doi": "10.2337/diacare.27.9.2251",
        "abstract": "In a cross-sectional study, high serum ferritin levels (a marker of body iron stores and inflammation) were strongly and independently associated with the presence of metabolic syndrome. The association was dose-dependent and present in both men and women."
      },
      "design": {
        "type": "cross-sectional",
        "n": 2901,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population (KNHANES)"
      },
      "variables": {
        "X": {
          "name": "bt ferritin  ",
          "unit": "ng/mL"
        },
        "Y": {
          "name": "bt triglycerides",
          "unit": "mmol/L"
        },
        "Z": [
          {
            "name": "waist circumference",
            "unit": "cm"
          },
          {
            "name": "bt glucose  ",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "Ferritin (X) -> Metabolic Syndrome (Y, Z1, Z2...)",
        "claim": "High serum ferritin (X) is a strong indicator of metabolic dysfunction. It is expected to be positively correlated with components of the metabolic syndrome in HPP, such as high triglycerides (Y), high waist circumference (Z1), and high glucose (Z2).",
        "assumptions": [
          "Ferritin reflects both iron stores and inflammation."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_ferritin_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "009-nmr_lipids",
          "field": "ng_triglycerides",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "002-anthropometrics",
            "field": "waist_circumference",
            "status": "exact"
          },
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_glucose_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt ggt float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-014",
      "paper": {
        "title": "Gamma-glutamyltransferase (GGT) and risk of metabolic syndrome: a meta-analysis of prospective cohort studies",
        "journal": "International Journal of Clinical Practice",
        "year": 2012,
        "tier": "A",
        "pmid": "22967117",
        "doi": "10.1111/j.1742-1241.2012.03001.x",
        "abstract": "This meta-analysis of 11 prospective studies (n=70,140) found that elevated serum GGT levels significantly increased the risk of developing metabolic syndrome. GGT, a marker of liver stress and oxidative stress, is strongly associated with insulin resistance and central obesity."
      },
      "design": {
        "type": "meta-analysis",
        "n": 70140,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "bt ggt  ",
          "unit": "U/L"
        },
        "Y": {
          "name": "Metabolic Syndrome (Composite)",
          "unit": "binary"
        },
        "Z": [
          {
            "name": "bt alt  ",
            "unit": "U/L"
          },
          {
            "name": "waist circumference",
            "unit": "cm"
          }
        ]
      },
      "inference": {
        "pathway": "GGT (X) -> Metabolic Syndrome (Y) | (ALT, Waist)",
        "claim": "GGT (X) is a strong, independent predictor of developing metabolic syndrome (Y). It is often elevated in HPP participants with liver fat (steatosis) and central obesity (Z2), even before ALT (Z1) becomes significantly high.",
        "assumptions": [
          "GGT reflects oxidative stress, not just alcohol use."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_ggt_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "derived",
          "field": "metabolic_syndrome_binary",
          "status": "derived"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_alt_float_value",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "waist_circumference",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt glucose float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-015",
      "paper": {
        "title": "Fasting Plasma Glucose and Risk of Type 2 Diabetes",
        "journal": "Diabetes Care",
        "year": 2002,
        "tier": "A+",
        "pmid": "12145239",
        "doi": "10.2337/diacare.25.10.1853",
        "abstract": "In a prospective cohort study, the risk of progressing to type 2 diabetes increased sharply with rising fasting plasma glucose (FPG) levels, even within the 'normal' range. FPG is the cornerstone for diagnosing pre-diabetes and diabetes."
      },
      "design": {
        "type": "prospective cohort",
        "n": 2092,
        "follow_up": "3.3 years"
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "non-diabetic at baseline"
      },
      "variables": {
        "X": {
          "name": "bt glucose  ",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "Type 2 Diabetes (Incident)",
          "unit": "binary"
        },
        "Z": [
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "Fasting Glucose (X) -> Future Diabetes (Y) | (BMI)",
        "claim": "Fasting glucose (X) is the primary biomarker for assessing current glycemic status and future diabetes risk (Y). In HPP, this value is interpreted alongside BMI (Z) and HbA1c.",
        "assumptions": [
          "Participant was fasting at time of blood draw."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_glucose_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_disease",
          "field": "t2d_incident",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt hba1c float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-016",
      "paper": {
        "title": "Association of haemoglobin A1c (HbA1c) with cardiovascular disease and mortality: a 10-year follow-up",
        "journal": "Diabetologia",
        "year": 2004,
        "tier": "A+",
        "pmid": "15365545",
        "doi": "10.1007/s00125-004-1529-1",
        "abstract": "In a large population-based cohort (EPIC-Norfolk), HbA1c levels were continuously associated with cardiovascular disease (CVD) and all-cause mortality, even in non-diabetic individuals. The risk increased across the entire distribution, showing no lower threshold."
      },
      "design": {
        "type": "prospective cohort",
        "n": 10232,
        "follow_up": "approx. 10 years"
      },
      "population": {
        "age": "45-79 years",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "bt hba1c  ",
          "unit": "%"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bt total cholesterol  ",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "HbA1c (X) -> CVD Event (Y) | (Age, Sex, Cholesterol)",
        "claim": "HbA1c (X), reflecting long-term (3-month) average glucose, is a powerful, independent predictor of future cardiovascular events (Y) and mortality, even in people without a diabetes diagnosis. It is a core metabolic risk marker in HPP.",
        "assumptions": [
          "HbA1c measured by standardized assay."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hba1c_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_total_cholesterol_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
      "id": "bt hdl cholesterol float value",
      "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-017",
      "paper": {
        "title": "HDL cholesterol and residual risk of first cardiovascular events after reduction of LDL cholesterol",
        "journal": "Circulation",
        "year": 2007,
        "tier": "A+",
        "pmid": "17967923",
        "doi": "10.1161/CIRCULATIONAHA.107.726117",
        "abstract": "In an analysis of patients on statin therapy, low HDL cholesterol remained a significant and independent predictor of future cardiovascular events, even after LDL cholesterol was aggressively lowered. This highlights HDL's role in 'residual risk'."
      },
      "design": {
        "type": "meta-analysis (post-hoc)",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "patients on statins"
      },
      "variables": {
        "X": {
          "name": "bt hdl cholesterol  ",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng ldl cholesterol",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "HDL-C (X) -> CVD Event (Y) | (LDL-C)",
        "claim": "Low HDL cholesterol (X), the 'good' cholesterol, is a major independent risk factor for cardiovascular events (Y). Its protective effect is distinct from the risk posed by high LDL cholesterol (Z1).",
        "assumptions": [
          "Causality is complex (genetics vs. lifestyle)."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hdl_cholesterol_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_lipids",
            "field": "ng_ldl_cholesterol",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
    "id": "bt hematocrit float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-018",
      "paper": {
        "title": "Hematocrit and risk of cardiovascular disease: The Framingham Heart Study",
        "journal": "American Heart Journal",
        "year": 1994,
        "tier": "A",
        "pmid": "8160679",
        "doi": "10.1016/0002-8703(94)90549-1",
        "abstract": "This long-term follow-up from the Framingham study found a U-shaped association. Both low hematocrit (anemia) and high hematocrit (polycythemia, increased blood viscosity) were independently associated with an increased risk of cardiovascular disease and mortality."
      },
      "design": {
        "type": "prospective cohort",
        "n": 5209,
        "follow_up": "26 years"
      },
      "population": {
        "age": "30-62 years",
        "sex": "both",
        "disease": "general population (Framingham)"
      },
      "variables": {
        "X": {
          "name": "bt hematocrit  ",
          "unit": "%"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "Hematocrit (X) -> CVD Event (Y) | (Age, Sex)",
        "claim": "Hematocrit (X), the percentage of blood volume occupied by red blood cells, has a U-shaped relationship with CVD risk (Y). Both low (anemia) and very high (viscosity) levels are detrimental. It is a key part of the complete blood count (CBC).",
        "assumptions": [
          "Excludes secondary causes of anemia/polycythemia."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hematocrit_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "bt hemoglobin float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-019",
      "paper": {
        "title": "Hemoglobin concentration and risk of stroke",
        "journal": "Stroke",
        "year": 2006,
        "tier": "A",
        "pmid": "16728670",
        "doi": "10.1161/01.STR.0000226462.65063.18",
        "abstract": "A meta-analysis of cohort studies found a J-shaped association between hemoglobin concentration and stroke risk. Risk was elevated for individuals with low hemoglobin (anemia) and also for those with very high hemoglobin levels, independent of traditional risk factors."
      },
      "design": {
        "type": "meta-analysis",
        "n": 222955,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "bt hemoglobin  ",
          "unit": "g/dL"
        },
        "Y": {
          "name": "Stroke Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "bt hematocrit  ",
            "unit": "%"
          }
        ]
      },
      "inference": {
        "pathway": "Hemoglobin (X) -> Stroke (Y)",
        "claim": "Hemoglobin (X), the oxygen-carrying protein in red blood cells, is a primary diagnostic marker for anemia. It is highly correlated with Hematocrit (Z1) and shows a J-shaped association with stroke risk (Y).",
        "assumptions": [
          "Hemoglobin and Hematocrit are ~1:3 ratio."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hemoglobin_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "stroke_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_hematocrit_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "bt rbc float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-020",
      "paper": {
        "title": "Red blood cell count and risk of type 2 diabetes: a systematic review and meta-analysis",
        "journal": "Diabetes/Metabolism Research and Reviews",
        "year": 2017,
        "tier": "A",
        "pmid": "27878932",
        "doi": "10.1002/dmrr.2862",
        "abstract": "This meta-analysis found a positive association between Red Blood Cell (RBC) count and the risk of developing type 2 diabetes. Higher RBC counts (within the normal range) were associated with increased risk, possibly due to mechanisms like increased viscosity or oxidative stress."
      },
      "design": {
        "type": "meta-analysis",
        "n": 81075,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "bt rbc  ",
          "unit": "x10^12/L"
        },
        "Y": {
          "name": "Type 2 Diabetes (Incident)",
          "unit": "binary"
        },
        "Z": [
          {
            "name": "bt hemoglobin  ",
            "unit": "g/dL"
          }
        ]
      },
      "inference": {
        "pathway": "RBC Count (X) -> Future Diabetes (Y)",
        "claim": "Red Blood Cell Count (X) is a component of the CBC, highly correlated with Hemoglobin (Z1) and Hematocrit. This meta-analysis links higher (but normal) RBC counts to increased metabolic risk, specifically for Type 2 Diabetes (Y).",
        "assumptions": [
          "Association, not causation"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_rbc_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_disease",
          "field": "t2d_incident",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_hemoglobin_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "bt rdw float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-021",
      "paper": {
        "title": "Red cell distribution width (RDW) and risk of mortality: a systematic review and meta-analysis",
        "journal": "Journal of Thoracic Disease",
        "year": 2017,
        "tier": "A",
        "pmid": "28523087",
        "doi": "10.21037/jtd.2017.04.13",
        "abstract": "This extensive meta-analysis showed that a high Red Cell Distribution Width (RDW), which indicates high variability in RBC size (anisocytosis), is a strong and independent predictor of all-cause mortality, particularly cardiovascular mortality, in both general and patient populations."
      },
      "design": {
        "type": "meta-analysis",
        "n": 10410,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general and patient populations"
      },
      "variables": {
        "X": {
          "name": "bt rdw  ",
          "unit": "%"
        },
        "Y": {
          "name": "All-cause mortality",
          "unit": "event"
        },
        "Z": [
          {
            "name": "bt hemoglobin  ",
            "unit": "g/dL"
          }
        ]
      },
      "inference": {
        "pathway": "RDW (X) -> Mortality (Y) | (Hemoglobin)",
        "claim": "RDW (X), a standard part of the CBC, is a powerful integrative biomarker. High RDW is strongly predictive of mortality (Y), independent of hemoglobin/anemia (Z1). It is thought to reflect systemic inflammation, oxidative stress, and poor erythropoiesis.",
        "assumptions": [
          "RDW reflects underlying systemic stress."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_rdw_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_mortality",
          "field": "all_cause_mortality",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_hemoglobin_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "bt rheumatoid factor float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-022",
      "paper": {
        "title": "Rheumatoid Factor and risk of cardiovascular disease: A systematic review and meta-analysis",
        "journal": "Arthritis & Rheumatology",
        "year": 2015,
        "tier": "A",
        "pmid": "25772390",
        "doi": "10.1002/art.39050",
        "abstract": "This meta-analysis found that positivity for Rheumatoid Factor (RF), even in the general population (without rheumatoid arthritis), is associated with an increased risk of cardiovascular disease (CVD). This suggests that the autoimmunity/inflammation represented by RF contributes to atherogenesis."
      },
      "design": {
        "type": "meta-analysis",
        "n": 67341,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "bt rheumatoid factor  ",
          "unit": "IU/mL"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "Rheumatoid Factor (X) -> CVD Event (Y) | (Age, Sex)",
        "claim": "Rheumatoid Factor (X) is a classic autoantibody. Its presence, even at low levels or without a clinical RA diagnosis, is a marker of systemic inflammation and is independently associated with a higher risk of future cardiovascular events (Y) in the HPP cohort.",
        "assumptions": [
          "Analysis excludes participants with diagnosed RA."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_rheumatoid_factor_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
    "id": "bt sodium float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-023",
      "paper": {
        "title": "Serum Sodium and Blood Pressure: A Population-Based Study",
        "journal": "The Journal of Clinical Hypertension",
        "year": 2019,
        "tier": "B",
        "pmid": "30680872",
        "doi": "10.1111/jch.13481",
        "abstract": "While dietary sodium intake is strongly linked to blood pressure, serum sodium is tightly regulated by hormones. This study found that serum sodium, even within the normal range, was positively and independently associated with systolic blood pressure in a general population, suggesting a link beyond just dietary intake."
      },
      "design": {
        "type": "cross-sectional",
        "n": 10580,
        "follow_up": null
      },
      "population": {
        "age": "18-79 years",
        "sex": "both",
        "disease": "general population (KNHANES)"
      },
      "variables": {
        "X": {
          "name": "bt sodium  ",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "sitting blood pressure systolic",
          "unit": "mmHg"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "Serum Sodium (X) -> Systolic BP (Y) | (Age, BMI)",
        "claim": "Serum sodium (X), a tightly regulated electrolyte, shows a positive correlation with systolic blood pressure (Y) in the HPP general population. This association is independent of age and BMI and reflects complex fluid/hormone balance.",
        "assumptions": [
          "Serum sodium is tightly regulated; variations are meaningful."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_sodium_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-blood_pressure",
          "field": "sitting_blood_pressure_systolic",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
    "id": "bt total bilirubin float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-024",
      "paper": {
        "title": "Serum total bilirubin and risk of cardiovascular disease in the framingham heart study",
        "journal": "Atherosclerosis",
        "year": 2016,
        "tier": "A",
        "pmid": "27131804",
        "doi": "10.1016/j.atherosclerosis.2016.03.033",
        "abstract": "In this large community-based sample (Framingham Offspring Study), higher serum total bilirubin concentrations were inversely associated with the risk of cardiovascular disease, coronary heart disease, and myocardial infarction. This supports the hypothesis that bilirubin, as an antioxidant, may be cardioprotective."
      },
      "design": {
        "type": "prospective cohort",
        "n": 2727,
        "follow_up": "median 29.6 years"
      },
      "population": {
        "age": "mean 43 years",
        "sex": "both",
        "disease": "general population (Framingham Offspring)"
      },
      "variables": {
        "X": {
          "name": "bt total bilirubin  ",
          "unit": "umol/L"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bt hdl cholesterol  ",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "Total Bilirubin (X) -> CVD Event (Y) | (Age, Sex, HDL)",
        "claim": "Higher levels of total bilirubin (X), often considered a waste product, are paradoxically associated with a *lower* risk of cardiovascular events (Y). This is thought to be due to its potent antioxidant properties. This is a key HPP finding for re-evaluating metabolic markers.",
        "assumptions": [
          "Excludes very high pathological levels (jaundice)."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_total_bilirubin_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_hdl_cholesterol_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "bt total cholesterol float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-025",
      "paper": {
        "title": "An App for That: The Framingham Heart Study Risk Score Calculator",
        "journal": "Circulation",
        "year": 2014,
        "tier": "A+",
        "pmid": "24842932",
        "doi": "10.1161/CIRCULATIONAHA.114.009548",
        "abstract": "The Framingham Risk Score (FRS) is a foundational algorithm used to estimate the 10-year risk of cardiovascular disease. Total Cholesterol is one of its original and most critical inputs, along with age, sex, HDL cholesterol, blood pressure, and smoking status."
      },
      "design": {
        "type": "risk score development / summary",
        "n": null,
        "follow_up": "10 years"
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "bt total cholesterol  ",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "10-Year CVD Risk (Framingham)",
          "unit": "%"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bt hdl cholesterol  ",
            "unit": "mmol/L"
          },
          {
            "name": "sitting blood pressure systolic",
            "unit": "mmHg"
          }
        ]
      },
      "inference": {
        "pathway": "Total Chol (X) + HDL (Z3) + SBP (Z4)... -> 10-Year CVD Risk (Y)",
        "claim": "Total Cholesterol (X) is a cornerstone of cardiovascular risk prediction. In HPP, it is a primary variable used in conjunction with HDL (Z3), SBP (Z4), age, and sex to calculate the Framingham Risk Score (Y) for participants.",
        "assumptions": [
          "Non-fasting total cholesterol is acceptable for FRS."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_total_cholesterol_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "derived",
          "field": "framingham_risk_score_10y",
          "status": "derived"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_hdl_cholesterol_float_value",
            "status": "exact"
          },
          {
            "dataset": "007-blood_pressure",
            "field": "sitting_blood_pressure_systolic",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "bt total protein float value",
    "group": 4,
    "content": {
      "evidence_id": "HPP-BLOOD-026",
      "paper": {
        "title": "Serum total protein and all-cause mortality: a 15.6-year follow-up of 40,000 adults",
        "journal": "Clinical Chemistry and Laboratory Medicine",
        "year": 2019,
        "tier": "A",
        "pmid": "30138090",
        "doi": "10.1515/cclm-2018-0628",
        "abstract": "In a large prospective cohort, a U-shaped association was found between serum total protein (TP) and all-cause mortality. Both low TP (<65 g/L) and high TP (>80 g/L) were associated with increased mortality risk, independent of albumin, age, and other confounders. Low TP often reflects malnutrition, while high TP can reflect chronic inflammation or gammopathies."
      },
      "design": {
        "type": "prospective cohort",
        "n": 40316,
        "follow_up": "median 15.6 years"
      },
      "population": {
        "age": "mean 47.9 years",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "bt total protein  ",
          "unit": "g/L"
        },
        "Y": {
          "name": "All-cause mortality",
          "unit": "event"
        },
        "Z": [
          {
            "name": "bt albumin  ",
            "unit": "g/L"
          }
        ]
      },
      "inference": {
        "pathway": "Total Protein (X) -> Mortality (Y) | (Albumin)",
        "claim": "Total Protein (X) has a U-shaped association with mortality (Y). It provides information beyond just albumin (Z1), as it also includes globulins. Low levels indicate malnutrition, while high levels can indicate inflammation. HPP measures both for a complete picture of protein status.",
        "assumptions": [
          "Globulin = Total Protein - Albumin"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_total_protein_float_value",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_mortality",
          "field": "all_cause_mortality",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_albumin_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "cgm 1st quartile",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001A",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "This key consensus paper standardized CGM reporting. While Time-in-Range (TIR) is the primary metric, Glycemic Variability (GV) is a critical secondary measure. The Interquartile Range (IQR, i.e., the range between the 1st Quartile/25th percentile and 3rd Quartile/75th percentile) is a simple, robust measure of GV. A wider IQR indicates greater glucose excursions and instability."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm 1st quartile",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "cgm 3rd quartile",
          "unit": "mmol/L"
        },
        "Z": []
      },
      "inference": {
        "pathway": "IQR [Y - X] -> Glycemic Variability",
        "claim": "The 1st Quartile (X, 25th percentile) and 3rd Quartile (Y, 75th percentile) are used to calculate the Interquartile Range (IQR). The IQR is a key HPP metric for quantifying Glycemic Variability, with a wider range indicating poorer glycemic control.",
        "assumptions": [
          "Based on standardized 14-day CGM recording."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_1st_quartile",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_3rd_quartile",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "cgm 3rd quartile",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001B",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "This key consensus paper standardized CGM reporting. While Time-in-Range (TIR) is the primary metric, Glycemic Variability (GV) is a critical secondary measure. The Interquartile Range (IQR, i.e., the range between the 1st Quartile/25th percentile and 3rd Quartile/75th percentile) is a simple, robust measure of GV. A wider IQR indicates greater glucose excursions and instability."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm 3rd quartile",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "cgm 1st quartile",
          "unit": "mmol/L"
        },
        "Z": []
      },
      "inference": {
        "pathway": "IQR [X - Y] -> Glycemic Variability",
        "claim": "The 3rd Quartile (X, 75th percentile) and 1st Quartile (Y, 25th percentile) are used to calculate the Interquartile Range (IQR). The IQR is a key HPP metric for quantifying Glycemic Variability, with a wider range indicating poorer glycemic control.",
        "assumptions": [
          "Based on standardized 14-day CGM recording."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_3rd_quartile",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_1st_quartile",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "cgm above 140",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001C",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "The consensus defines Time-Above-Range (TAR) as the percentage of time glucose is > 180 mg/dL (10.0 mmol/L). It also defines a Level 1 Hyperglycemia (Time in 'High' Glucose) as time spent between 180 mg/dL and 250 mg/dL. Time spent above 140 mg/dL (7.8 mmol/L) is also a common metric, especially for tighter control (e.g., T1D pregnancy)."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm above 140 (mg/dL)",
          "unit": "% time"
        },
        "Y": {
          "name": "cgm above 180 (mg/dL)",
          "unit": "% time"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Time Above 140 (X) -> Hyperglycemia Metric",
        "claim": "This variable is the 'Time Above Range' (TAR) using a 140 mg/dL (7.8 mmol/L) threshold. It is a sensitive measure of hyperglycemia, stricter than the standard 180 mg/dL (Y) threshold, and is a key output of the HPP CGM processing pipeline.",
        "assumptions": [
          "Represents percentage of 24-hour period."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_above_140",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_above_180",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "cgm above 180",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001D",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "The international consensus defines Time-Above-Range (TAR), or Level 1 Hyperglycemia, as the percentage of time spent with glucose values > 180 mg/dL (10.0 mmol/L). For most T1D and T2D patients, the goal is to minimize this, aiming for < 25% of the day."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm above 180 (mg/dL)",
          "unit": "% time"
        },
        "Y": {
          "name":"bt hba1c  ",
          "unit": "%"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Time Above Range (X) -> HbA1c (Y)",
        "claim": "Time-Above-Range (TAR) at 180 mg/dL (X) is a standard CGM metric for hyperglycemia. It is strongly correlated with HbA1c (Y) but provides actionable, intra-day information that HbA1c cannot. The HPP goal is to minimize this value.",
        "assumptions": [
          "Represents percentage of 24-hour period."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_above_180",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hba1c_float_value",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "cgm above 250",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001E",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "The consensus defines Level 2 Hyperglycemia (Time in 'Very High' Glucose) as the percentage of time spent > 250 mg/dL (13.9 mmol/L). This level represents clinically significant hyperglycemia, a high priority for intervention, with a target of < 5% of the day for most patients."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm above 250 (mg/dL)",
          "unit": "% time"
        },
        "Y": {
          "name": "Diabetic Ketoacidosis (DKA) risk",
          "unit": "risk level"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Time Above 250 (X) -> DKA Risk (Y)",
        "claim": "Time spent 'Very High' (X, >250 mg/dL) is a critical CGM metric. It represents a severe lack of glycemic control and, especially in T1D, significantly increases the short-term risk of adverse events like DKA (Y). HPP aims to minimize this value to near 0%.",
        "assumptions": [
          "Represents percentage of 24-hour period."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_above_250",
          "status": "exact"
        },
        "Y": {
          "dataset": "derived",
          "field": "dka_risk_level",
          "status": "derived"
        }
      }
    }
  },
  {
    "id": "cgm below 54",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001F",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "The consensus defines Level 2 Hypoglycemia (Time in 'Very Low' Glucose) as the percentage of time spent < 54 mg/dL (3.0 mmol/L). This is a clinically dangerous state, representing severe hypoglycemia, and is a top priority to eliminate. The target for all patients is < 1% of the day."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm below 54 (mg/dL)",
          "unit": "% time"
        },
        "Y": {
          "name": "Severe Hypoglycemia Event",
          "unit": "event"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Time Below 54 (X) -> Severe Hypo Event (Y)",
        "claim": "Time spent 'Very Low' (X, <54 mg/dL) is the most critical CGM safety metric. It represents time in a neuroglycopenic state, with high risk of immediate cognitive impairment or loss of consciousness (Y). The HPP target is < 1%.",
        "assumptions": [
          "Represents percentage of 24-hour period."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_below_54",
          "status": "exact"
        },
        "Y": {
          "dataset": "000-questionnaire",
          "field": "severe_hypo_event_report",
          "status": "inferred"
        }
      }
    }
  },
  {
    "id": "cgm below 70",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001G",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "The consensus defines Time-Below-Range (TBR), or Level 1 Hypoglycemia, as the percentage of time spent with glucose values < 70 mg/dL (3.9 mmol/L). This is the standard alert threshold for hypoglycemia. For most T1D and T2D patients, the goal is to minimize this, aiming for < 4% of the day."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm below 70 (mg/dL)",
          "unit": "% time"
        },
        "Y": {
          "name": "cgm below 54 (mg/dL)",
          "unit": "% time"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Time Below 70 (X) -> Hypoglycemia Burden",
        "claim": "Time-Below-Range (TBR) at 70 mg/dL (X) is the standard CGM metric for total hypoglycemia burden. It includes the more dangerous 'Very Low' time (Y, <54 mg/dL). Minimizing TBR (X) is a primary goal of safe glycemic control in the HPP cohort.",
        "assumptions": [
          "TBR (X) includes TBR (Y). Value X >= Y."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_below_70",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_below_54",
          "status": "exact"
        }
      }
    }
  },
    {
    "id": "cgm in range 63 140",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-002",
      "paper": {
        "title": "Continuous Glucose Monitoring in Healthy Nondiabetic Adults",
        "journal": "The Journal of Clinical Endocrinology & Metabolism",
        "year": 2019,
        "tier": "A",
        "pmid": "30698717",
        "doi": "10.1210/jc.2018-02434",
        "abstract": "This study used CGM in a large cohort of healthy, non-diabetic adults to define normoglycemia. It found that the 2.5th to 97.5th percentile range for glucose was 63-140 mg/dL (3.5-7.8 mmol/L). This range is often used as a 'healthy' or 'non-diabetic' target."
      },
      "design": {
        "type": "observational cohort",
        "n": 153,
        "follow_up": null
      },
      "population": {
        "age": "18-76 years",
        "sex": "both",
        "disease": "healthy non-diabetic"
      },
      "variables": {
        "X": {
          "name": "cgm in range 63 140 (mg/dL)",
          "unit": "% time"
        },
        "Y": {
          "name": "cgm in range 70 180 (mg/dL)",
          "unit": "% time"
        },
        "Z": []
      },
      "inference": {
        "pathway": "TIR (63-140) (X) vs TIR (70-180) (Y)",
        "claim": "The 'Time in Range' (TIR) of 63-140 mg/dL (X) represents the time spent within the normal physiological range observed in healthy, non-diabetic individuals. It is a stricter target than the standard diabetes target of 70-180 mg/dL (Y) and is a key metric in HPP for assessing pre-diabetic risk.",
        "assumptions": [
          "Healthy population baseline"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_in_range_63_140",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_in_range_70_180",
          "status": "exact"
        }
      }
    }
  },
    {
    "id": "cgm in range 70 180",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001H",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "The international consensus defines the primary therapeutic target, Time-in-Range (TIR), as the percentage of time spent with glucose values between 70 mg/dL (3.9 mmol/L) and 180 mg/dL (10.0 mmol/L). For most T1D and T2D patients, the goal is >70% of the day in this range."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm in range 70 180 (mg/dL)",
          "unit": "% time"
        },
        "Y": {
          "name": "bt hba1c  ",
          "unit": "%"
        },
        "Z": [
          {
            "name": "cgm cv",
            "unit": "%"
          }
        ]
      },
      "inference": {
        "pathway": "TIR (X) -> HbA1c (Y) & Glycemic Variability (Z1)",
        "claim": "Time-in-Range (TIR) 70-180 mg/dL (X) is the single most important CGM metric for overall glycemic control. It is strongly (inversely) correlated with HbA1c (Y) and the risk of complications. It is the primary target for HPP participants with diabetes, balanced against variability (Z1).",
        "assumptions": [
          "TIR is the standard international target."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_in_range_70_180",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hba1c_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "005-cgm",
            "field": "cgm_cv",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "cgm adrr",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-003A",
      "paper": {
        "title": "Quantifying of errors in glucose measurement and glucose variability",
        "journal": "Diabetes Technology & Therapeutics",
        "year": 2007,
        "tier": "A",
        "pmid": "17381341",
        "doi": "10.1089/dia.2006.0028",
        "abstract": "This paper by Kovatchev et al. introduces the concept of the Average Daily Risk Range (ADRR). ADRR is a measure of glycemic variability that specifically weights excursions into hypoglycemia and hyperglycemia based on their associated risk. It is derived from the High Blood Glucose Index (HBGI) and Low Blood Glucose Index (LBGI)."
      },
      "design": {
        "type": "metric development / mathematical modeling",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm adrr",
          "unit": "risk score"
        },
        "Y": {
          "name": "cgm hbgi",
          "unit": "risk score"
        },
        "Z": [
          {
            "name": "cgm lbgi",
            "unit": "risk score"
          }
        ]
      },
      "inference": {
        "pathway": "ADRR (X) = f(HBGI (Y), LBGI (Z1))",
        "claim": "The Average Daily Risk Range (ADRR) (X) is a sophisticated HPP metric for glycemic variability. It is calculated from the High (Y) and Low (Z1) Blood Glucose Indices, providing a single score that quantifies the *risk* of glucose excursions, not just their statistical range.",
        "assumptions": [
          "Kovatchev risk transformation formula"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_adrr",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_hbgi",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "005-cgm",
            "field": "cgm_lbgi",
            "status": "inferred (Low Blood Glucose Index)"
          }
        ]
      }
    }
  },
  {
    "id": "cgm auc",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-004",
      "paper": {
        "title": "Glucose and insulin area under the curve (AUC) responses to common foods",
        "journal": "The American Journal of Clinical Nutrition",
        "year": 2017,
        "tier": "A",
        "pmid": "28855260",
        "doi": "10.3945/ajcn.117.153610",
        "abstract": "Area Under the Curve (AUC) is a fundamental metric for quantifying total glycemic exposure after a stimulus (e.g., a meal). The incremental AUC (iAUC) measures the glucose rise above the fasting baseline. CGM data allows for the calculation of 24-hour total AUC, a measure of total daily glycemic load."
      },
      "design": {
        "type": "observational / protocol",
        "n": 29,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "healthy"
      },
      "variables": {
        "X": {
          "name": "cgm auc",
          "unit": "(mg/dL) * min"
        },
        "Y": {
          "name": "cgm mean",
          "unit": "mg/dL"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Total AUC (X) / Time -> Mean Glucose (Y)",
        "claim": "Total 24-hour Area Under the Curve (AUC) (X) is a measure of the total glycemic exposure over the day. It is mathematically related to the Mean Glucose (Y) (i.e., AUC / 1440 minutes = Mean). HPP uses this metric to quantify total glycemic load.",
        "assumptions": [
          "AUC calculated by trapezoidal rule from CGM data."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_auc_24h",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_mean",
          "status": "inferred"
        }
      }
    }
  },
    {
    "id": "cgm cogi",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-005",
      "paper": {
        "title": "COGI: a new index for continuous glucose monitoring data",
        "journal": "Diabetes Technology & Therapeutics",
        "year": 2017,
        "tier": "B",
        "pmid": "28165910",
        "doi": "10.1089/dia.2016.0357",
        "abstract": "The Continuous Overall Glycemic Index (COGI) was proposed as a novel single metric to assess overall glucose control quality. It is a formula that combines Time-in-Range (70-180), Time-Below-Range (<70), and Mean Glucose into one score, designed to correlate strongly with HbA1c."
      },
      "design": {
        "type": "metric development",
        "n": 100,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm cogi",
          "unit": "index score"
        },
        "Y": {
          "name": "bt hba1c  ",
          "unit": "%"
        },
        "Z": [
          {
            "name": "cgm in range 70 180",
            "unit": "%"
          },
          {
            "name": "cgm below 70",
            "unit": "%"
          }
        ]
      },
      "inference": {
        "pathway": "COGI (X) = f(TIR (Z1), TBR (Z2), Mean) -> Correlates with HbA1c (Y)",
        "claim": "COGI (X) is a composite index measured in HPP, designed to provide a single-value summary of glycemic control quality. It combines TIR (Z1), TBR (Z2), and mean glucose, and is strongly correlated with HbA1c (Y).",
        "assumptions": [
          "COGI formula as defined by Leal et al."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_cogi",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hba1c_float_value",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "005-cgm",
            "field": "cgm_in_range_70_180",
            "status": "exact"
          },
          {
            "dataset": "005-cgm",
            "field": "cgm_below_70",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "cgm conga",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-006",
      "paper": {
        "title": "CONGA: a new method for analysis of glucose variability from continuous glucose monitoring data",
        "journal": "Diabetes Technology & Therapeutics",
        "year": 2005,
        "tier": "A",
        "pmid": "16321151",
        "doi": "10.1089/dia.2005.7.830",
        "abstract": "Continuous Overall Net Glycemic Action (CONGA) is a measure of glycemic variability. It is calculated as the standard deviation of the differences between glucose values at a specific time 't' and 't-n' (e.g., n=1, 2, 4 hours). It quantifies the 'swing' or fluctuation of glucose over a defined time interval."
      },
      "design": {
        "type": "metric development",
        "n": 10,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "Type 1 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm conga (e.g., n=2h)",
          "unit": "mg/dL"
        },
        "Y": {
          "name": "cgm cv",
          "unit": "%"
        },
        "Z": []
      },
      "inference": {
        "pathway": "CONGA (X) -> Glycemic Variability",
        "claim": "CONGA (X) is an HPP metric for quantifying glycemic variability (GV) over a specific time lag (e.g., 2 hours). It captures the average magnitude of glucose 'swings' and is used as a measure of glycemic instability, complementary to other GV metrics like CV (Y).",
        "assumptions": [
          "CONGA(n) where 'n' is the time lag in hours."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_conga",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_cv",
          "status": "exact"
        }
      }
    }
  },
    {
    "id": "cgm cv",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-001I",
      "paper": {
        "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range",
        "journal": "Diabetes Care",
        "year": 2019,
        "tier": "A+",
        "pmid": "31177182",
        "doi": "10.2337/dci19-0028",
        "abstract": "The international consensus established the Coefficient of Variation (CV) as the standard measure for glycemic variability. CV (calculated as Standard Deviation / Mean Glucose * 100%) is a key metric. A CV < 36% is the target for stable glycemic control, while CV > 36% indicates unstable control, regardless of HbA1c."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "Type 1 & Type 2 Diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm cv",
          "unit": "%"
        },
        "Y": {
          "name": "cgm below 70",
          "unit": "%"
        },
        "Z": [
          {
            "name": "cgm mean",
            "unit": "mg/dL"
          },
          {
            "name": "cgm sd",
            "unit": "mg/dL"
          }
        ]
      },
      "inference": {
        "pathway": "CV (X) = (SD (Z2) / Mean (Z1)) * 100. CV (X) -> Hypoglycemia Risk (Y)",
        "claim": "The Coefficient of Variation (CV) (X) is the consensus standard for HPP glycemic variability. It is calculated from the mean (Z1) and standard deviation (Z2) of glucose. High CV (>36%) is a critical finding, as it is strongly linked to a higher risk of hypoglycemia (Y), independent of mean glucose.",
        "assumptions": [
          "CV < 36% is the clinical target for stability."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_cv",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_below_70",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "005-cgm",
            "field": "cgm_mean",
            "status": "inferred"
          },
          {
            "dataset": "005-cgm",
            "field": "cgm_sd",
            "status": "inferred"
          }
        ]
      }
    }
  },
  {
    "id": "cgm cv measures mean",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-007",
      "paper": {
        "title": "Translating the A1C assay into estimated average glucose values",
        "journal": "Diabetes Care",
        "year": 2008,
        "tier": "A+",
        "pmid": "18463235",
        "doi": "10.2337/dc08-0560",
        "abstract": "The ADAG (A1C-Derived Average Glucose) study established a linear regression formula linking mean glucose (MG) from CGM with HbA1c. This allows for the 'Estimated Average Glucose' (eAG). Mean Glucose is the average of all CGM values, typically over 14 days, and is the denominator for calculating the Coefficient of Variation (CV)."
      },
      "design": {
        "type": "observational cohort",
        "n": 507,
        "follow_up": null
      },
      "population": {
        "age": "adults & adolescents",
        "sex": "both",
        "disease": "Type 1, Type 2, & non-diabetic"
      },
      "variables": {
        "X": {
          "name": "cgm mean",
          "unit": "mg/dL"
        },
        "Y": {
          "name": "bt hba1c  ",
          "unit": "%"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Mean Glucose (X) <-> HbA1c (Y)",
        "claim": "This node represents the 'Mean Glucose' (average of all CGM readings). It is the most direct measure of central glycemic tendency from CGM and is strongly correlated with HbA1c (Y) via the ADAG formula (eAG). It is also the denominator used to calculate CV. [ID 'cgm cv measures mean' interpreted as 'cgm mean']",
        "assumptions": [
          "Node ID 'cgm cv measures mean' is interpreted as 'Mean Glucose'."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_mean",
          "status": "inferred (from ID 'cgm cv measures mean')"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hba1c_float_value",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "cgm gvp",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-008",
      "paper": {
        "title": "GVP (Glycemic Variability Percentage): A New, Simple, and Reliable Index of Glycemic Variability",
        "journal": "Diabetes Technology & Therapeutics",
        "year": 2018,
        "tier": "B",
        "pmid": "30325176",
        "doi": "10.1089/dia.2018.0185",
        "abstract": "The Glycemic Variability Percentage (GVP) was proposed as a simple, novel metric for glycemic variability. It is calculated from the mean absolute difference between consecutive glucose readings (i.e., Mean Absolute Glucose, MAG) divided by the mean glucose. It is designed to be a robust alternative to CV."
      },
      "design": {
        "type": "metric development",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm gvp",
          "unit": "%"
        },
        "Y": {
          "name": "cgm cv",
          "unit": "%"
        },
        "Z": [
          {
            "name": "cgm mean",
            "unit": "mg/dL"
          }
        ]
      },
      "inference": {
        "pathway": "GVP (X) = (MAG / Mean (Z1)) * 100. GVP (X) ~ CV (Y)",
        "claim": "GVP (X) is another HPP metric for glycemic variability. It is based on the Mean Absolute Glucose (MAG) change and is highly correlated with the Coefficient of Variation (CV) (Y), but is argued to be simpler to calculate and interpret.",
        "assumptions": [
          "GVP formula as defined by Pe-Gvp et al."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_gvp",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_cv",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "005-cgm",
            "field": "cgm_mean",
            "status": "inferred"
          }
        ]
      }
    }
  },
    {
    "id": "cgm hbgi",
    "group": 5,
    "content": {
      "evidence_id": "HPP-CGM-003B",
      "paper": {
        "title": "Quantification of errors in glucose measurement and glucose variability",
        "journal": "Diabetes Technology & Therapeutics",
        "year": 2007,
        "tier": "A",
        "pmid": "17381341",
        "doi": "10.1089/dia.2006.0028",
        "abstract": "This paper by Kovatchev et al. defines the High Blood Glucose Index (HBGI). HBGI is a non-linear transformation of glucose values (f(glucose) = (ln(glucose)^a - b)^c) that 'weights' hyperglycemic excursions based on their risk. A higher HBGI indicates a higher number and/or severity of high glucose events."
      },
      "design": {
        "type": "metric development / mathematical modeling",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "diabetes"
      },
      "variables": {
        "X": {
          "name": "cgm hbgi",
          "unit": "risk score"
        },
        "Y": {
          "name": "cgm above 180",
          "unit": "% time"
        },
        "Z": []
      },
      "inference": {
        "pathway": "HBGI (X) = f(Glucose readings > 180)",
        "claim": "The High Blood Glucose Index (HBGI) (X) is a key HPP risk metric. Unlike 'Time Above 180' (Y), which treats all high values equally, HBGI (X) assigns a much higher risk 'penalty' to a reading of 300 mg/dL than to 190 mg/dL. It quantifies the *severity* of hyperglycemia.",
        "assumptions": [
          "Kovatchev risk transformation formula"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "005-cgm",
          "field": "cgm_hbgi",
          "status": "exact"
        },
        "Y": {
          "dataset": "005-cgm",
          "field": "cgm_above_180",
          "status": "exact"
        }
      }
    }
  },
    {
      "id": "cgm hyper index",
      "group": 5
    },
    {
      "id": "cgm daily cogi",
      "group": 5
    },
    {
      "id": "cgm daily gvp",
      "group": 5
    },
    {
      "id": "cgm daily hbgi",
      "group": 5
    },
    {
    "id": "ahi",
    "group": 6,
    "content": {
      "evidence_id": "HPP-SLEEP-001",
      "paper": {
        "title": "Sleep-disordered breathing and mortality: a systematic review and meta-analysis",
        "journal": "Journal of Clinical Sleep Medicine",
        "year": 2013,
        "tier": "A+",
        "pmid": "23801891",
        "doi": "10.5664/jcsm.2820",
        "abstract": "This large meta-analysis synthesized data on the relationship between the ApneaHypopnea Index (AHI) and mortality. It found a significant association, showing that severe obstructive sleep apnea (OSA), defined by a high AHI (e.g., AHI >= 30), is independently associated with increased all-cause mortality."
      },
      "design": {
        "type": "meta-analysis",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general & clinical cohorts"
      },
      "variables": {
        "X": {
          "name": "ahi (ApneaHypopnea Index)",
          "unit": "events/hour"
        },
        "Y": {
          "name": "All-cause mortality",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          },
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "AHI (X) -> All-Cause Mortality (Y) | (Age, Sex, BMI)",
        "claim": "The ApneaHypopnea Index (AHI) (X) is the primary HPP metric for diagnosing sleep apnea severity. A high AHI (e.g., >30 events/hour) is a strong, independent risk factor for all-cause mortality (Y), even after adjusting for confounders like BMI (Z3).",
        "assumptions": [
          "AHI measured by in-home sleep test (e.g., WatchPAT) or PSG."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-sleep",
          "field": "ahi",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_mortality",
          "field": "all_cause_mortality",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          },
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
    "id": "imt left",
    "group": 7,
    "content": {
      "evidence_id": "HPP-IMT-001A",
      "paper": {
        "title": "Carotid intima-media thickness (IMT) and risk of stroke: a meta-analysis",
        "journal": "JAMA",
        "year": 2007,
        "tier": "A+",
        "pmid": "17327540",
        "doi": "10.1001/jama.297.11.1211",
        "abstract": "This is a landmark meta-analysis (ARIC, CHS, FHS, etc.) that established carotid intima-media thickness (IMT) as a strong, independent predictor of future cardiovascular events. Increased IMT (measured in the common carotid) is directly associated with a higher risk of first-time stroke and myocardial infarction."
      },
      "design": {
        "type": "meta-analysis of prospective cohorts",
        "n": 14917,
        "follow_up": "median 10.9 years"
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "imt left (Common Carotid)",
          "unit": "mm"
        },
        "Y": {
          "name": "Stroke Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "Age",
            "unit": "years"
          },
          {
            "name": "Sex",
            "unit": null
          }
        ]
      },
      "inference": {
        "pathway": "Left Carotid IMT (X) -> Stroke Risk (Y) | (Age, Sex)",
        "claim": "Carotid Intima-Media Thickness (IMT) (X) is a key HPP measure of subclinical atherosclerosis. Increased thickness in the left carotid artery is a powerful, independent predictor of future stroke (Y) and cardiovascular disease, even after adjusting for traditional risk factors.",
        "assumptions": [
          "Standardized B-mode ultrasound protocol."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-imt",
          "field": "imt_left_cca_mean",
          "status": "inferred (from ID 'imt left')"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "stroke_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "standard",
            "field": "age",
            "status": "exact"
          },
          {
            "dataset": "standard",
            "field": "sex",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "imt right",
    "group": 7,
    "content": {
      "evidence_id": "HPP-IMT-001B",
      "paper": {
        "title": "Right-left asymmetry of common carotid intima-media thickness: a population-based study",
        "journal": "Stroke",
        "year": 2004,
        "tier": "A",
        "pmid": "14681530",
        "doi": "10.1161/01.STR.0000106456.84882.35",
        "abstract": "This study specifically investigated differences between left and right carotid IMT. It found that while left and right IMT are highly correlated, the right IMT was, on average, slightly thinner than the left. However, both were independently predictive of cardiovascular risk. Most protocols (like MESA) use the mean of both sides."
      },
      "design": {
        "type": "cross-sectional",
        "n": 1030,
        "follow_up": null
      },
      "population": {
        "age": "30-79 years",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "imt right (Common Carotid)",
          "unit": "mm"
        },
        "Y": {
          "name": "imt left (Common Carotid)",
          "unit": "mm"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Right IMT (X) vs Left IMT (Y) -> CVD Risk",
        "claim": "HPP measures IMT on the right side (X) in addition to the left (Y). Both are highly correlated and predictive of CVD risk. The mean of left and right IMT is often used as the final composite measure of subclinical atherosclerosis.",
        "assumptions": [
          "Standardized B-mode ultrasound protocol."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-imt",
          "field": "imt_right_cca_mean",
          "status": "inferred (from ID 'imt right')"
        },
        "Y": {
          "dataset": "007-imt",
          "field": "imt_left_cca_mean",
          "status": "inferred"
        }
      }
    }
  },
  {
    "id": "imt window width left",
    "group": 7,
    "content": {
      "evidence_id": "HPP-IMT-002A",
      "paper": {
        "title": "Automated B-mode ultrasound measurement of carotid intima-media thickness: a methods paper",
        "journal": "Radiology",
        "year": 1998,
        "tier": "A (Methodology)",
        "pmid": "9574488",
        "doi": "10.1148/radiology.207.2.9574488",
        "abstract": "This foundational paper describes an automated edge-detection system for measuring IMT. The method involves defining a region of interest (ROI), or 'window', on the ultrasound image. The 'window width' (length of the ROI) is a key parameter that must be standardized (e.g., 10 mm) to ensure reproducible measurements across studies."
      },
      "design": {
        "type": "methodology / software",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "n/a",
        "sex": "n/a",
        "disease": "n/a"
      },
      "variables": {
        "X": {
          "name": "imt window width left",
          "unit": "mm (pixels)"
        },
        "Y": {
          "name": "imt left",
          "unit": "mm"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Window Width (X) -> Used to Calculate IMT (Y)",
        "claim": "This variable (X) is not a biological measurement, but a Quality Control (QC) parameter from the HPP ultrasound software. It defines the length (e.g., 10 mm) of the 'window' or Region of Interest (ROI) on the left carotid artery used to calculate the mean IMT (Y).",
        "assumptions": [
          "Standardized protocol parameter."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-imt-QC",
          "field": "imt_window_width_left",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-imt",
          "field": "imt_left",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "imt window width right",
    "group": 7,
    "content": {
      "evidence_id": "HPP-IMT-002B",
      "paper": {
        "title": "Automated B-mode ultrasound measurement of carotid intima-media thickness: a methods paper",
        "journal": "Radiology",
        "year": 1998,
        "tier": "A (Methodology)",
        "pmid": "9574488",
        "doi": "10.1148/radiology.207.2.9574488",
        "abstract": "."
      },
      "design": {
        "type": "methodology / software",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "n/a",
        "sex": "n/a",
        "disease": "n/a"
      },
      "variables": {
        "X": {
          "name": "imt window width right",
          "unit": "mm (pixels)"
        },
        "Y": {
          "name": "imt right",
          "unit": "mm"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Window Width (X) -> Used to Calculate IMT (Y)",
        "claim": "This variable (X) is a Quality Control (QC) parameter from the HPP ultrasound software. It defines the length (e.g., 10 mm) of the 'window' or Region of Interest (ROI) on the right carotid artery used to calculate the mean IMT (Y).",
        "assumptions": [
          "Standardized protocol parameter."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-imt-QC",
          "field": "imt_window_width_right",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-imt",
          "field": "imt_right",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "imt fit left",
    "group": 7,
    "content": {
      "evidence_id": "HPP-IMT-003A",
      "paper": {
        "title": "Carotid Artery Intima-Media Thickness (CIMT) Measurement in B-Mode Ultrasound: A Review of Methods",
        "journal": "IEEE Transactions on Medical Imaging",
        "year": 2011,
        "tier": "A (Methodology)",
        "pmid": "21382747",
        "doi": "10.1109/TMI.2011.2127201",
        "abstract": "This review discusses automated IMT measurement algorithms. These algorithms 'fit' lines to the lumen-intima and media-adventitia interfaces. The quality of this 'fit' (e.g., R-squared, cost function, or correlation coefficient) is a critical QC metric to ensure the automated measurement is accurate and not based on noise or poor image quality."
      },
      "design": {
        "type": "review / methodology",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "n/a",
        "sex": "n/a",
        "disease": "n/a"
      },
      "variables": {
        "X": {
          "name": "imt fit left",
          "unit": "quality score (e.g., 0-1)"
        },
        "Y": {
          "name": "imt left",
          "unit": "mm"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Fit Quality (X) -> Validates Measurement (Y)",
        "claim": "This variable (X) is a Quality Control (QC) metric from the HPP ultrasound software. It represents the 'goodness of fit' (e.g., correlation score) of the automated edge detection for the left IMT (Y). A low score indicates a poor quality, unreliable measurement that should be excluded from analysis.",
        "assumptions": [
          "QC metric for automated line fitting."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-imt-QC",
          "field": "imt_fit_left",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-imt",
          "field": "imt_left",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "imt fit right",
    "group": 7,
    "content": {
      "evidence_id": "HPP-IMT-003B",
      "paper": {
        "title": "Carotid Artery Intima-Media Thickness (CIMT) Measurement in B-Mode Ultrasound: A Review of Methods",
        "journal": "IEEE Transactions on Medical Imaging",
        "year": 2011,
        "tier": "A (Methodology)",
        "pmid": "21382747",
        "doi": "10.1109/TMI.2011.212747",
        "abstract": "This review discusses automated IMT measurement algorithms. These algorithms 'fit' lines to the lumen-intima and media-adventitia interfaces. The quality of this 'fit' (e.g., R-squared, cost function, or correlation coefficient) is a critical QC metric to ensure the automated measurement is accurate and not based on noise or poor image quality."
      },
      "design": {
        "type": "review / methodology",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "n/a",
        "sex": "n/a",
        "disease": "n/a"
      },
      "variables": {
        "X": {
          "name": "imt fit right",
          "unit": "quality score (e.g., 0-1)"
        },
        "Y": {
          "name": "imt right",
          "unit": "mm"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Fit Quality (X) -> Validates Measurement (Y)",
        "claim": "This variable (X) is a Quality Control (QC) metric from the HPP ultrasound software. It represents the 'goodness of fit' (e.g., correlation score) of the automated edge detection for the right IMT (Y). A low score indicates a poor quality, unreliable measurement.",
        "assumptions": [
          "QC metric for automated line fitting."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "007-imt-QC",
          "field": "imt_fit_right",
          "status": "exact"
        },
        "Y": {
          "dataset": "007-imt",
          "field": "imt_right",
          "status": "exact"
        }
      }
    }
  },
    {
    "id": "liver elasticity 2D SWE",
    "group": 8,
    "content": {
      "evidence_id": "HPP-LIVER-001",
      "paper": {
        "title": "2D Shear Wave Elastography (2D-SWE) for the diagnosis of liver fibrosis: A systematic review and meta-analysis",
        "journal": "Journal of Hepatology",
        "year": 2017,
        "tier": "A+",
        "pmid": "28167210",
        "doi": "10.1016/j.jhep.2017.01.019",
        "abstract": "This meta-analysis establishes 2D Shear Wave Elastography (2D-SWE) as a highly accurate non-invasive method for diagnosing and staging liver fibrosis. Liver stiffness (elasticity), measured in kilopascals (kPa), correlates strongly with the Metavir fibrosis stage, with higher kPa values indicating more severe fibrosis/cirrhosis."
      },
      "design": {
        "type": "meta-analysis / diagnostic accuracy",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "chronic liver disease"
      },
      "variables": {
        "X": {
          "name": "liver elasticity 2D SWE",
          "unit": "kPa"
        },
        "Y": {
          "name": "Liver Fibrosis Stage (METAVIR)",
          "unit": "F0-F4"
        },
        "Z": [
          {
            "name": "bt alt  ",
            "unit": "U/L"
          }
        ]
      },
      "inference": {
        "pathway": "Liver Elasticity (X) -> Fibrosis Stage (Y)",
        "claim": "Liver Elasticity (X), measured in kPa via 2D-SWE, is the primary HPP non-invasive marker for liver fibrosis (scarring). Higher values (e.g., > 7-10 kPa) are strongly indicative of significant fibrosis (>=F2) and are often associated with chronic liver inflammation (high ALT, Z1).",
        "assumptions": [
          "Measurement must be high quality (e.g., 10 valid shots)."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "008-liver_ultrasound",
          "field": "liver_elasticity_2D_SWE",
          "status": "exact"
        },
        "Y": {
          "dataset": "derived",
          "field": "fibrosis_stage_inferred",
          "status": "derived"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_alt_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "liver viscosity vi plus",
    "group": 8,
    "content": {
      "evidence_id": "HPP-LIVER-002",
      "paper": {
        "title": "Viscosity-based new parameter from 2D shear-wave elastography for non-invasive assessment of hepatic inflammation",
        "journal": "Hepatology International",
        "year": 2020,
        "tier": "B",
        "pmid": "31900650",
        "doi": "10.1007/s12072-019-10012-7",
        "abstract": "This study investigated a new parameter, shear wave dispersion slope (viscosity), derived from 2D-SWE. It found that while elasticity (kPa) primarily reflects fibrosis, viscosity (m/s/kHz or Pas) is more strongly correlated with the grade of hepatic inflammation (necroinflammation), a key feature of NASH."
      },
      "design": {
        "type": "observational cohort",
        "n": 100,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "biopsy-proven NAFLD"
      },
      "variables": {
        "X": {
          "name": "liver viscosity (Vi Plus)",
          "unit": "Pas"
        },
        "Y": {
          "name": "Inflammation Grade (NASH)",
          "unit": "score"
        },
        "Z": [
          {
            "name": "liver elasticity 2D SWE",
            "unit": "kPa"
          }
        ]
      },
      "inference": {
        "pathway": "Liver Viscosity (X) -> Inflammation Grade (Y) | (Fibrosis, Z1)",
        "claim": "Liver Viscosity (X) is an advanced HPP metric from SWE. Unlike elasticity (Z1) which measures fibrosis, viscosity (X) is a novel marker for active liver *inflammation*. This allows HPP to distinguish between simple fibrosis and active inflammatory disease (NASH).",
        "assumptions": [
          "Measures shear wave dispersion slope."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "008-liver_ultrasound",
          "field": "liver_viscosity_vi_plus",
          "status": "exact"
        },
        "Y": {
          "dataset": "derived",
          "field": "inflammation_grade_inferred",
          "status": "derived"
        },
        "Z": [
          {
            "dataset": "008-liver_ultrasound",
            "field": "liver_elasticity_2D_SWE",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "liver attenuation index att plus",
    "group": 8,
    "content": {
      "evidence_id": "HPP-LIVER-003",
      "paper": {
        "title": "Attenuation imaging for non-invasive quantification of hepatic steatosis",
        "journal": "World Journal of Gastroenterology",
        "year": 2018,
        "tier": "A",
        "pmid": "29713133",
        "doi": "10.3748/wjg.v24.i16.1797",
        "abstract": "Ultrasound-guided attenuation parameters, such as the Attenuation Coefficient (ATT) or Attenuation Index (ATI), are novel methods for quantifying hepatic steatosis (fatty liver). The ultrasound signal attenuates (weakens) as it passes through fat. A higher attenuation value (in dB/cm/MHz) is strongly correlated with a higher grade of steatosis."
      },
      "design": {
        "type": "review / diagnostic accuracy",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "NAFLD"
      },
      "variables": {
        "X": {
          "name": "liver attenuation index att plus",
          "unit": "dB/cm/MHz"
        },
        "Y": {
          "name": "Hepatic Steatosis Grade (S0-S3)",
          "unit": "grade"
        },
        "Z": [
          {
            "name": "bmi",
            "unit": "kg/m^2"
          }
        ]
      },
      "inference": {
        "pathway": "Attenuation Index (X) -> Steatosis Grade (Y)",
        "claim": "The Liver Attenuation Index (X) is the primary HPP non-invasive marker for hepatic steatosis (liver fat). A higher attenuation value (X) signifies more fat in the liver, and is strongly correlated with steatosis grade (Y) and often with high BMI (Z1).",
        "assumptions": [
          "Measures ultrasound signal decay due to fat."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "008-liver_ultrasound",
          "field": "liver_attenuation_index_att_plus",
          "status": "exact"
        },
        "Y": {
          "dataset": "derived",
          "field": "steatosis_grade_inferred",
          "status": "derived"
        },
        "Z": [
          {
            "dataset": "002-anthropometrics",
            "field": "bmi",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "liver speed of sound ssp plus",
    "group": 8,
    "content": {
      "evidence_id": "HPP-LIVER-004",
      "paper": {
        "title": "Sound speed of shear wave as an index of hepatic steatosis",
        "journal": "Journal of Medical Ultrasonics",
        "year": 2017,
        "tier": "B",
        "pmid": "27878696",
        "doi": "10.1007/s10396-016-0761-1",
        "abstract": "This study proposes that the speed of sound (SS) of the shear wave itself (distinct from elasticity or attenuation) can also be used to detect steatosis. It found that sound speed *decreases* as the fat content (steatosis grade) increases. This provides a complementary metric to attenuation for fat quantification."
      },
      "design": {
        "type": "observational",
        "n": 68,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "NAFLD vs. controls"
      },
      "variables": {
        "X": {
          "name": "liver speed of sound ssp plus",
          "unit": "m/s"
        },
        "Y": {
          "name": "liver attenuation index att plus",
          "unit": "dB/cm/MHz"
        },
        "Z": []
      },
      "inference": {
        "pathway": "Sound Speed (X) <-> Attenuation (Y)",
        "claim": "Liver Sound Speed (X) is another HPP metric for liver fat. Unlike attenuation (Y), which *increases* with fat, sound speed (X) *decreases* with fat. The two metrics (X and Y) are expected to be strongly negatively correlated and are used together to improve the accuracy of steatosis grading.",
        "assumptions": [
          "Sound speed in fat is lower than in water/tissue."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "008-liver_ultrasound",
          "field": "liver_speed_of_sound_ssp_plus",
          "status": "exact"
        },
        "Y": {
          "dataset": "008-liver_ultrasound",
          "field": "liver_attenuation_index_att_plus",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "ng total cholesterol",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-001",
      "paper": {
        "title": "Lipoprotein(a) and Risk of Cardiovascular Disease in the UK Biobank",
        "journal": "Circulation",
        "year": 2019,
        "tier": "A+",
        "pmid": "31394986",
        "doi": "10.1161/CIRCULATIONAHA.119.041818",
        "abstract": "The UK Biobank used the Nightingale Health (NG) NMR platform to measure lipids for >100,000 participants. This paper (and many others from UKB) confirms the utility of NMR-derived lipids. NMR Total Cholesterol is a key component, highly correlated with standard enzymatic assays but derived from the sum of all cholesterol in lipoprotein particles."
      },
      "design": {
        "type": "prospective cohort",
        "n": 103982,
        "follow_up": "median 10.1 years"
      },
      "population": {
        "age": "40-69 years",
        "sex": "both",
        "disease": "UK Biobank cohort"
      },
      "variables": {
        "X": {
          "name": "ng total cholesterol (NMR)",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "bt total cholesterol (Enzymatic)",
          "unit": "mmol/L"
        },
        "Z": []
      },
      "inference": {
        "pathway": "NMR Total Chol (X) <-> Enzymatic Total Chol (Y)",
        "claim": "This variable (X) is Total Cholesterol as measured by the Nightingale (NG) NMR platform. It is expected to be very highly correlated (R > 0.95) with the standard blood test (Y, 'bt total cholesterol'). The NMR platform provides this value as part of a much larger, comprehensive lipid panel.",
        "assumptions": [
          "NMR sum of VLDL, IDL, LDL, and HDL cholesterol."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_total_cholesterol",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_total_cholesterol_float_value",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "ng ldl cholesterol",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-002",
      "paper": {
        "title": "NMR-derived LDL cholesterol vs. calculated LDL: impact on risk stratification",
        "journal": "Clinical Chemistry",
        "year": 2014,
        "tier": "A",
        "pmid": "24434638",
        "doi": "10.1373/clinchem.2013.216656",
        "abstract": "This study compares directly measured LDL-C from NMR (like Nightingale) to the standard calculated LDL-C (Friedewald equation). It found that NMR-measured LDL-C is more accurate, especially in patients with high triglycerides, and reclassifies cardiovascular risk for a significant number of individuals."
      },
      "design": {
        "type": "method comparison / cohort",
        "n": 1337,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "statin-treated patients"
      },
      "variables": {
        "X": {
          "name": "ng ldl cholesterol (NMR)",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "Calculated LDL Cholesterol",
          "unit": "mmol/L"
        },
        "Z": [
          {
            "name": "ng triglycerides",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "NMR LDL (X) -> More Accurate CVD Risk than Calculated LDL (Y)",
        "claim": "Nightingale (NG) LDL Cholesterol (X) is a direct measurement of LDL-C from the NMR spectrum. Unlike standard calculated LDL (Y), its accuracy is not affected by high triglycerides (Z1). HPP uses this as a more precise measure of atherogenic cholesterol burden.",
        "assumptions": [
          "Direct measurement, not calculated."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_ldl_cholesterol",
          "status": "exact"
        },
        "Y": {
          "dataset": "derived",
          "field": "ldl_calculated_friedewald",
          "status": "derived"
        },
        "Z": [
          {
            "dataset": "009-nmr_lipids",
            "field": "ng_triglycerides",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng hdl cholesterol",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-003",
      "paper": {
        "title": "NMR-derived HDL-C: comparison with standard enzymatic assays",
        "journal": "UK Biobank Documentation / Nightingale Health",
        "year": 2019,
        "tier": "Methodology",
        "pmid": null,
        "doi": null,
        "abstract": "The Nightingale (NG) NMR platform measures HDL-C as the sum of cholesterol within all 4 HDL subfractions (Large, Medium, Small, Very Small). This value is highly correlated (R > 0.9) with the standard enzymatic 'bt hdl cholesterol' but provides the basis for deeper subfraction analysis."
      },
      "design": {
        "type": "method comparison",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "n/a",
        "sex": "n/a",
        "disease": "n/a"
      },
      "variables": {
        "X": {
          "name": "ng hdl cholesterol (NMR)",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "bt hdl cholesterol (Enzymatic)",
          "unit": "mmol/L"
        },
        "Z": []
      },
      "inference": {
        "pathway": "NMR HDL Chol (X) <-> Enzymatic HDL Chol (Y)",
        "claim": "This variable (X) is HDL Cholesterol as measured by the Nightingale (NG) NMR platform. It is highly correlated with the standard blood test (Y, 'bt hdl cholesterol'). Its primary value in HPP is serving as the total for the NMR-specific HDL subfractions (e.g., Large HDL-C).",
        "assumptions": [
          "NMR sum of HDL subfraction cholesterol."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_hdl_cholesterol",
          "status": "exact"
        },
        "Y": {
          "dataset": "004-blood_biochemistry",
          "field": "bt_hdl_cholesterol_float_value",
          "status": "exact"
        }
      }
    }
  },
  {
    "id": "ng triglycerides",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-004",
      "paper": {
        "title": "Triglycerides and cardiovascular risk: an update",
        "journal": "Current Opinion in Lipidology",
        "year": 2017,
        "tier": "A",
        "pmid": "28151752",
        "doi": "10.1097/MOL.0000000000000398",
        "abstract": "Triglycerides (TG) are recognized as a major independent risk factor for CVD. NMR-based quantification (like Nightingale) measures the total TG content across all lipoprotein fractions (VLDL, IDL, LDL, HDL) and is a robust measure of triglyceride-rich lipoprotein (TRL) burden."
      },
      "design": {
        "type": "review",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "CVD risk"
      },
      "variables": {
        "X": {
          "name": "ng triglycerides (NMR)",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng ldl cholesterol",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "Triglycerides (X) -> CVD Event (Y) | (LDL-C, Z1)",
        "claim": "Nightingale (NG) Total Triglycerides (X) is a key HPP marker for metabolic health and CVD risk. High triglycerides (X) are a major component of metabolic syndrome and are predictive of CVD events (Y), independent of LDL cholesterol (Z1).",
        "assumptions": [
          "NMR sum of TG in all lipoprotein fractions."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_triglycerides",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_lipids",
            "field": "ng_ldl_cholesterol",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng apolipoprotein a1",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-005",
      "paper": {
        "title": "Apolipoprotein A-I (ApoA-I) and cardiovascular risk",
        "journal": "Circulation",
        "year": 2006,
        "tier": "A+",
        "pmid": "16461849",
        "doi": "10.1161/CIRCULATIONAHA.104.512028",
        "abstract": "Apolipoprotein A-I (ApoA-I) is the primary structural protein of HDL particles. Serum concentration of ApoA-I is a strong inverse predictor of cardiovascular risk. Some studies suggest ApoA-I is a more consistent marker of cardioprotection than HDL-C itself, as it reflects the *number* of HDL particles."
      },
      "design": {
        "type": "review / meta-analysis",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "CVD risk"
      },
      "variables": {
        "X": {
          "name": "ng apolipoprotein a1 (ApoA-I)",
          "unit": "g/L"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng hdl cholesterol",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "ApoA-I (X) -> Inverse CVD Risk (Y)",
        "claim": "Apolipoprotein A-I (X) is the main protein on HDL particles, measured by HPP's NMR platform. Low levels of ApoA-I (X) are a strong, independent predictor of higher cardiovascular risk (Y), and it is often considered a better marker than HDL-C (Z1) because it reflects HDL particle *concentration*.",
        "assumptions": [
          "ApoA-I is the best measure of anti-atherogenic particle count."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_apolipoprotein_a1",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_lipids",
            "field": "ng_hdl_cholesterol",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng apolipoprotein b",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-006",
      "paper": {
        "title": "Apolipoprotein B (ApoB) and cardiovascular risk: a consensus statement",
        "journal": "Atherosclerosis",
        "year": 2020,
        "tier": "A+",
        "pmid": "32709448",
        "doi": "10.1016/j.atherosclerosis.2020.07.005",
        "abstract": "This consensus statement affirms that Apolipoprotein B (ApoB) is the most accurate measure of atherogenic lipoprotein burden. Since every VLDL, IDL, and LDL particle contains exactly one ApoB molecule, the ApoB concentration directly equals the total *number* of atherogenic particles. It is superior to LDL-C for risk assessment."
      },
      "design": {
        "type": "consensus guideline",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "CVD risk assessment"
      },
      "variables": {
        "X": {
          "name": "ng apolipoprotein b (ApoB)",
          "unit": "g/L"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng ldl cholesterol",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "ApoB (X) -> Total Atherogenic Particle Count -> CVD Risk (Y)",
        "claim": "Apolipoprotein B (ApoB) (X) is arguably the most important atherogenic marker measured in HPP. It directly reflects the total *concentration* of all 'bad' cholesterol particles (VLDL, LDL, etc.). High ApoB (X) is a stronger predictor of CVD events (Y) than LDL-C (Z1) alone.",
        "assumptions": [
          "One ApoB molecule per atherogenic particle."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_apolipoprotein_b",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_lipids",
            "field": "ng_ldl_cholesterol",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng ldl particle size",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-007",
      "paper": {
        "title": "Small, dense LDL particles and cardiovascular disease: a meta-analysis",
        "journal": "Archives of Internal Medicine",
        "year": 2009,
        "tier": "A",
        "pmid": "19901140",
        "doi": "10.1001/archinternmed.2009.384",
        "abstract": "This meta-analysis confirmed that small, dense LDL (sdLDL) particles are significantly more atherogenic than large, buoyant LDL particles. A smaller average LDL particle size is a key feature of the 'atherogenic lipid phenotype' (high TG, low HDL) and is independently associated with increased CVD risk, even for the same total LDL-C."
      },
      "design": {
        "type": "meta-analysis",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "CVD risk"
      },
      "variables": {
        "X": {
          "name": "ng ldl particle size",
          "unit": "nm"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng triglycerides",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "High TGs (Z1) -> Small LDL Size (X) -> High CVD Risk (Y)",
        "claim": "Average LDL Particle Size (X) is a key advanced metric from the HPP NMR panel. A *smaller* size (X) indicates a predominance of small, dense, highly atherogenic particles. This phenotype is strongly correlated with high triglycerides (Z1) and is a powerful predictor of CVD risk (Y).",
        "assumptions": [
          "Weighted average size of all LDL particles."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_ldl_particle_size",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_lipids",
            "field": "ng_triglycerides",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
    "id": "ng vldl particle conc",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-008",
      "paper": {
        "title": "VLDL particles in type 2 diabetes and cardiovascular disease",
        "journal": "Metabolism",
        "year": 2017,
        "tier": "A",
        "pmid": "28183467",
        "doi": "10.1016/j.metabol.2016.12.003",
        "abstract": "VLDL (Very-Low-Density Lipoprotein) particles are the primary transporters of triglycerides from the liver. High concentration of VLDL particles is a hallmark of metabolic syndrome and insulin resistance. These particles are highly atherogenic, both as precursors to LDL and on their own (as 'remnant' particles)."
      },
      "design": {
        "type": "review",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "T2D / MetS / CVD"
      },
      "variables": {
        "X": {
          "name": "ng vldl particle conc",
          "unit": "mol/L"
        },
        "Y": {
          "name": "ng triglycerides",
          "unit": "mmol/L"
        },
        "Z": [
          {
            "name": "bt hba1c  ",
            "unit": "%"
          }
        ]
      },
      "inference": {
        "pathway": "Insulin Resistance (Z1) -> High VLDL-P (X) & High TGs (Y)",
        "claim": "VLDL Particle Concentration (X), measured by HPP's NMR, is a direct count of these triglyceride-rich particles. It is a key marker of insulin resistance (Z1) and is expected to be extremely highly correlated with Total Triglycerides (Y), as VLDL is the main carrier of TGs.",
        "assumptions": [
          "VLDL-P is a major component of ApoB."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_vldl_particle_conc",
          "status": "exact"
        },
        "Y": {
          "dataset": "009-nmr_lipids",
          "field": "ng_triglycerides",
          "status": "exact"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_hba1c_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng hdl particle conc",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-009",
      "paper": {
        "title": "HDL particle number and incident cardiovascular disease: the MESA study",
        "journal": "JAMA Cardiology",
        "year": 2016,
        "tier": "A+",
        "pmid": "27438150",
        "doi": "10.1001/jamacardio.2016.1417",
        "abstract": "The MESA study (Multi-Ethnic Study of Atherosclerosis) found that HDL Particle Concentration (HDL-P), measured by NMR, was more strongly and inversely associated with future cardiovascular disease risk than the standard HDL-C (cholesterol content) measurement. Low particle count, regardless of cholesterol content, signifies impaired reverse cholesterol transport."
      },
      "design": {
        "type": "prospective cohort",
        "n": 6814,
        "follow_up": "median 10.1 years"
      },
      "population": {
        "age": "45-84 years",
        "sex": "both",
        "disease": "general population (MESA)"
      },
      "variables": {
        "X": {
          "name": "ng hdl particle conc (HDL-P)",
          "unit": "mol/L"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng hdl cholesterol (HDL-C)",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "HDL-P (X) -> Inverse CVD Risk (Y) (Stronger than HDL-C, Z1)",
        "claim": "HDL Particle Concentration (X) is a key HPP metric, considered by many to be superior to standard HDL-C (Z1). A *low* count of HDL particles (X) is a very strong independent predictor of *high* cardiovascular risk (Y), as it reflects the capacity of the reverse cholesterol transport system.",
        "assumptions": [
          "Particle count is a better functional marker than cholesterol mass."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_lipids",
          "field": "ng_hdl_particle_conc",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_lipids",
            "field": "ng_hdl_cholesterol",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng omega 3 pct",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-010",
      "paper": {
        "title": "Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review",
        "journal": "JAMA",
        "year": 2018,
        "tier": "A+",
        "pmid": "29340671",
        "doi": "10.1001/jama.2017.21829",
        "abstract": "Omega-3 fatty acids (DHA and EPA) are strongly linked to cardiovascular health. Measuring the percentage of total fatty acids that are Omega-3 (O3%) is a key biomarker of both dietary intake and cardiovascular protection. Higher O3% is associated with lower triglycerides and reduced risk of cardiac events."
      },
      "design": {
        "type": "meta-analysis / review",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "CVD risk"
      },
      "variables": {
        "X": {
          "name": "ng omega 3 pct",
          "unit": "% of total FAs"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng triglycerides",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "Omega 3 % (X) -> Lower TGs (Z1) -> Lower CVD Risk (Y)",
        "claim": "The percentage of Omega-3 fatty acids (X) in plasma, measured by HPP's NMR, is a critical biomarker of dietary intake and metabolic health. A higher O3% is associated with lower triglycerides (Z1) and is considered cardioprotective, reducing risk of CVD (Y).",
        "assumptions": [
          "Reflects EPA + DHA levels primarily."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_metabolomics",
          "field": "ng_omega_3_pct",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_lipids",
            "field": "ng_triglycerides",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng omega 6 pct",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-011",
      "paper": {
        "title": "Omega-6 fatty acids and risk of cardiovascular disease: a science advisory from the AHA",
        "journal": "Circulation",
        "year": 2009,
        "tier": "A+",
        "pmid": "19171857",
        "doi": "10.1161/CIRCULATIONAHA.108.191627",
        "abstract": "The role of Omega-6 (O6) fatty acids is complex. This AHA advisory concludes that O6 FAs (like linoleic acid) are *cardioprotective* and *reduce* CVD risk, contrary to popular belief. The ratio of O6/O3 is also important, but high O6 itself is not detrimental and is in fact beneficial when replacing saturated fats."
      },
      "design": {
        "type": "science advisory / review",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "all",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "ng omega 6 pct",
          "unit": "% of total FAs"
        },
        "Y": {
          "name": "CVD Event",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng omega 3 pct",
            "unit": "%"
          }
        ]
      },
      "inference": {
        "pathway": "Omega 6 % (X) -> Inverse CVD Risk (Y). O6/O3 Ratio (X/Z1) also relevant.",
        "claim": "The percentage of Omega-6 fatty acids (X) is a key HPP biomarker. Contrary to some myths, higher O6% (X) is associated with *lower* cardiovascular risk (Y). HPP measures both O6 (X) and O3 (Z1) to assess the full profile of polyunsaturated fats.",
        "assumptions": [
          "Primarily reflects linoleic acid."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_metabolomics",
          "field": "ng_omega_6_pct",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_cvd",
          "field": "cvd_event",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_metabolomics",
            "field": "ng_omega_3_pct",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng polyunsaturated fatty acids pct",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-012",
      "paper": {
        "title": "Serum Polyunsaturated Fatty Acids (PUFA) and risk of all-cause mortality: The MESA study",
        "journal": "The American Journal of Clinical Nutrition",
        "year": 2014,
        "tier": "A",
        "pmid": "25411283",
        "doi": "10.3945/ajcn.114.095712",
        "abstract": "In the MESA cohort, higher levels of total polyunsaturated fatty acids (PUFA), as a percentage of total FAs, were inversely associated with all-cause mortality. This suggests that the total amount of 'good fats' (both O3 and O6) is a strong indicator of better health and lower mortality risk."
      },
      "design": {
        "type": "prospective cohort",
        "n": 6814,
        "follow_up": "median 7.8 years"
      },
      "population": {
        "age": "45-84 years",
        "sex": "both",
        "disease": "general population (MESA)"
      },
      "variables": {
        "X": {
          "name": "ng polyunsaturated fatty acids pct (PUFA %)",
          "unit": "% of total FAs"
        },
        "Y": {
          "name": "All-cause mortality",
          "unit": "event"
        },
        "Z": [
          {
            "name": "ng omega 3 pct",
            "unit": "%"
          },
          {
            "name": "ng omega 6 pct",
            "unit": "%"
          }
        ]
      },
      "inference": {
        "pathway": "PUFA % (X) = O3% (Z1) + O6% (Z2). PUFA % (X) -> Inverse Mortality (Y)",
        "claim": "Total Polyunsaturated Fatty Acids (PUFA) % (X) is a composite HPP biomarker representing the sum of Omega-3 (Z1) and Omega-6 (Z2) percentages. A higher total PUFA % (X) is strongly associated with reduced all-cause mortality (Y).",
        "assumptions": [
          "PUFA % = O3% + O6%"
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_metabolomics",
          "field": "ng_polyunsaturated_fatty_acids_pct",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_mortality",
          "field": "all_cause_mortality",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_metabolomics",
            "field": "ng_omega_3_pct",
            "status": "exact"
          },
          {
            "dataset": "009-nmr_metabolomics",
            "field": "ng_omega_6_pct",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng branched chain amino acids",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-013",
      "paper": {
        "title": "Branched-Chain Amino Acids (BCAAs) and risk of future diabetes: a meta-analysis",
        "journal": "The American Journal of Clinical Nutrition",
        "year": 2014,
        "tier": "A+",
        "pmid": "25008874",
        "doi": "10.3945/ajcn.114.084054",
        "abstract": "This landmark meta-analysis established that elevated circulating levels of Branched-Chain Amino Acids (BCAAs: leucine, isoleucine, valine) are a very strong and early predictor of future Type 2 Diabetes, independent of traditional risk factors. High BCAAs reflect impaired BCAA catabolism, a key feature of insulin resistance."
      },
      "design": {
        "type": "meta-analysis of prospective cohorts",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "ng branched chain amino acids (BCAA)",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "Type 2 Diabetes (Incident)",
          "unit": "binary"
        },
        "Z": [
          {
            "name": "bt hba1c  ",
            "unit": "%"
          }
        ]
      },
      "inference": {
        "pathway": "Insulin Resistance -> High BCAAs (X) -> Future T2D (Y)",
        "claim": "Elevated Branched-Chain Amino Acids (BCAAs) (X) is a top-tier metabolic biomarker in HPP. High BCAA levels are a very strong, independent predictor of future Type 2 Diabetes (Y), often appearing years before high HbA1c (Z1). They are a key marker of early insulin resistance.",
        "assumptions": [
          "Sum of leucine, isoleucine, and valine."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_metabolomics",
          "field": "ng_branched_chain_amino_acids",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_disease",
          "field": "t2d_incident",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_hba1c_float_value",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng glutamine",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-014",
      "paper": {
        "title": "Circulating Glutamine and Risk of Type 2 Diabetes: A Mendelian Randomization Study",
        "journal": "Diabetes",
        "year": 2019,
        "tier": "A",
        "pmid": "31189679",
        "doi": "10.2337/db19-0142",
        "abstract": "In contrast to BCAAs, this study (and others) found that *low* circulating glutamine levels are associated with an *increased* risk of developing Type 2 Diabetes. Glutamine is involved in glucose metabolism and insulin secretion, and low levels may indicate metabolic dysfunction."
      },
      "design": {
        "type": "mendelian randomization / cohort",
        "n": null,
        "follow_up": null
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population"
      },
      "variables": {
        "X": {
          "name": "ng glutamine",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "Type 2 Diabetes (Incident)",
          "unit": "binary"
        },
        "Z": [
          {
            "name": "ng branched chain amino acids",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "Low Glutamine (X) -> Increased Future T2D (Y)",
        "claim": "Glutamine (X) is an important HPP amino acid biomarker. Unlike BCAAs (Z1) which are *positively* correlated with risk, *low* glutamine levels (X) are predictive of an *increased* risk for future Type 2 Diabetes (Y).",
        "assumptions": [
          "Glutamine/BCAA ratio is a key metabolic marker."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_metabolomics",
          "field": "ng_glutamine",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_disease",
          "field": "t2d_incident",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_metabolomics",
            "field": "ng_branched_chain_amino_acids",
            "status": "exact"
          }
        ]
      }
    }
  },
  {
    "id": "ng citrate",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-015",
      "paper": {
        "title": "Plasma citrate and risk of type 2 diabetes and cardiovascular disease: the PREVEND study",
        "journal": "Diabetologia",
        "year": 2017,
        "tier": "A",
        "pmid": "28168351",
        "doi": "10.1007/s00125-017-4217-1",
        "abstract": "This prospective study found that *high* plasma citrate levels were independently associated with an *increased* risk of both future Type 2 Diabetes and cardiovascular disease. Citrate is a key intermediate in the TCA (Krebs) cycle and high circulating levels may reflect mitochondrial dysfunction and overload, a core aspect of insulin resistance."
      },
      "design": {
        "type": "prospective cohort",
        "n": 3995,
        "follow_up": "median 10.5 years"
      },
      "population": {
        "age": "mean 49 years",
        "sex": "both",
        "disease": "general population (PREVEND)"
      },
      "variables": {
        "X": {
          "name": "ng citrate",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "Type 2 Diabetes (Incident)",
          "unit": "binary"
        },
        "Z": [
          {
            "name": "ng branched chain amino acids",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "Mitochondrial Dysfunction -> High Citrate (X) -> Future T2D (Y)",
        "claim": "Citrate (X) is a key HPP metabolite from the TCA cycle. Like high BCAAs (Z1), *high* circulating citrate (X) is a powerful, independent predictor of future Type 2 Diabetes (Y) and CVD, reflecting a state of metabolic overload and mitochondrial stress.",
        "assumptions": [
          "High plasma citrate reflects 'mitochondrial overflow'."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_metabolomics",
          "field": "ng_citrate",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_disease",
          "field": "t2d_incident",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "009-nmr_metabolomics",
            "field": "ng_branched_chain_amino_acids",
            "status": "exact"
          }
        ]
      }
    }
  },
    {
    "id": "ng ketone bodies",
    "group": 9,
    "content": {
      "evidence_id": "HPP-NMR-016",
      "paper": {
        "title": "Circulating ketone bodies and risk of type 2 diabetes in a prospective cohort study",
        "journal": "Diabetes & Metabolism",
        "year": 2019,
        "tier": "B",
        "pmid": "30468822",
        "doi": "10.1016/j.diabet.2018.11.006",
        "abstract": "This study found that higher levels of total ketone bodies (beta-hydroxybutyrate and acetoacetate) in the non-fasting state were paradoxically associated with an *increased* risk of future Type 2 Diabetes. This state of 'mild ketosis' in the presence of insulin resistance may reflect inflexible fuel switching and metabolic stress, rather than healthy dietary ketosis."
      },
      "design": {
        "type": "prospective cohort",
        "n": 10030,
        "follow_up": "median 7.7 years"
      },
      "population": {
        "age": "adults",
        "sex": "both",
        "disease": "general population (Finnish)"
      },
      "variables": {
        "X": {
          "name": "ng ketone bodies (total)",
          "unit": "mmol/L"
        },
        "Y": {
          "name": "Type 2 Diabetes (Incident)",
          "unit": "binary"
        },
        "Z": [
          {
            "name": "bt glucose  ",
            "unit": "mmol/L"
          }
        ]
      },
      "inference": {
        "pathway": "Insulin Resistance -> High Ketones (X) + High Glucose (Z1) -> Future T2D (Y)",
        "claim": "Total Ketone Bodies (X) measured by HPP NMR are a marker of fat oxidation. While high ketones can be healthy (dietary ketosis), the presence of *both* high ketones (X) and high glucose (Z1) is pathological, indicating metabolic inflexibility and a high risk of future Type 2 Diabetes (Y).",
        "assumptions": [
          "Sum of beta-hydroxybutyrate and acetoacetate."
        ]
      },
      "hpp_mapping": {
        "X": {
          "dataset": "009-nmr_metabolomics",
          "field": "ng_ketone_bodies",
          "status": "exact"
        },
        "Y": {
          "dataset": "follow_up_disease",
          "field": "t2d_incident",
          "status": "inferred"
        },
        "Z": [
          {
            "dataset": "004-blood_biochemistry",
            "field": "bt_glucose_float_value",
            "status": "exact"
          }
        ]
      }
    }
  }
  ],
  "links": [
    {
      "source": "year of birth",
      "target": "height",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "weight",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "bmi",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "waist circumference",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "hip circumference",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "neck circumference",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "waist to hip ratio",
      "value": 2
    },
    {
      "source": "sex",
      "target": "height",
      "value": 2
    },
    {
      "source": "sex",
      "target": "weight",
      "value": 2
    },
    {
      "source": "sex",
      "target": "bmi",
      "value": 2
    },
    {
      "source": "sex",
      "target": "waist circumference",
      "value": 2
    },
    {
      "source": "sex",
      "target": "hip circumference",
      "value": 2
    },
    {
      "source": "sex",
      "target": "neck circumference",
      "value": 2
    },
    {
      "source": "sex",
      "target": "waist to hip ratio",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "lying blood pressure diastolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "lying blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "sitting blood pressure systolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "sitting blood pressure diastolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "sitting blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "sitting second blood pressure systolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "sitting second blood pressure diastolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "sitting second blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "standing one min blood pressure systolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "standing one min blood pressure diastolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "standing one min blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "standing three min blood pressure systolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "standing three min blood pressure diastolic",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "standing three min blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "blood pressure hand",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "dizziness",
      "value": 2
    },
    {
      "source": "sex",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "lying blood pressure diastolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "lying blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "sex",
      "target": "sitting blood pressure systolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "sitting blood pressure diastolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "sitting blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "sex",
      "target": "sitting second blood pressure systolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "sitting second blood pressure diastolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "sitting second blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "sex",
      "target": "standing one min blood pressure systolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "standing one min blood pressure diastolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "standing one min blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "sex",
      "target": "standing three min blood pressure systolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "standing three min blood pressure diastolic",
      "value": 2
    },
    {
      "source": "sex",
      "target": "standing three min blood pressure pulse rate",
      "value": 2
    },
    {
      "source": "sex",
      "target": "blood pressure hand",
      "value": 2
    },
    {
      "source": "sex",
      "target": "dizziness",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "imt right",
      "value": 2
    },
    {
      "source": "sex",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "sex",
      "target": "imt right",
      "value": 2
    },
    {
      "source": "year of birth",
      "target": "ahi",
      "value": 2
    },
    {
      "source": "sex",
      "target": "ahi",
      "value": 2
    },
    {
      "source": "bmi",
      "target": "lying blood pressure systolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "lying blood pressure diastolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "sitting blood pressure systolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "sitting blood pressure diastolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "sitting second blood pressure systolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "sitting second blood pressure diastolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "standing one min blood pressure systolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "standing one min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "standing three min blood pressure systolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "standing three min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "lying blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "lying blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "sitting blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "sitting blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "sitting second blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "sitting second blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "standing one min blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "standing one min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "standing three min blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "standing three min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "lying blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "lying blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "sitting blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "sitting blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "sitting second blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "sitting second blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "standing one min blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "standing one min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "standing three min blood pressure systolic",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "standing three min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "lying blood pressure systolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "lying blood pressure diastolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "sitting blood pressure systolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "sitting blood pressure diastolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "sitting second blood pressure systolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "sitting second blood pressure diastolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "standing one min blood pressure systolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "standing one min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "standing three min blood pressure systolic",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "standing three min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "lying blood pressure systolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "lying blood pressure diastolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "sitting blood pressure systolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "sitting blood pressure diastolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "sitting second blood pressure systolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "sitting second blood pressure diastolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "standing one min blood pressure systolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "standing one min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "standing three min blood pressure systolic",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "standing three min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "liver elasticity 2D SWE",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "liver viscosity vi plus",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "liver attenuation index att plus",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "liver speed of sound ssp plus",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "liver elasticity 2D SWE",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "liver viscosity vi plus",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "liver attenuation index att plus",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "liver speed of sound ssp plus",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "liver elasticity 2D SWE",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "liver viscosity vi plus",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "liver attenuation index att plus",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "liver speed of sound ssp plus",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "liver elasticity 2D SWE",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "liver viscosity vi plus",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "liver attenuation index att plus",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "liver speed of sound ssp plus",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "liver elasticity 2D SWE",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "liver viscosity vi plus",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "liver attenuation index att plus",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "liver speed of sound ssp plus",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "bt glucose float value",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "bt hba1c float value",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "cgm auc",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "cgm cv",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "cgm hbgi",
      "value": 4
    },
    {
      "source": "bmi",
      "target": "cgm above 180",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "bt glucose float value",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "bt hba1c float value",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "cgm auc",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "cgm cv",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "cgm hbgi",
      "value": 4
    },
    {
      "source": "waist circumference",
      "target": "cgm above 180",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "bt glucose float value",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "bt hba1c float value",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "cgm auc",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "cgm cv",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "cgm hbgi",
      "value": 4
    },
    {
      "source": "waist to hip ratio",
      "target": "cgm above 180",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "bt glucose float value",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "bt hba1c float value",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "cgm auc",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "cgm cv",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "cgm hbgi",
      "value": 4
    },
    {
      "source": "neck circumference",
      "target": "cgm above 180",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "bt glucose float value",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "bt hba1c float value",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "cgm auc",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "cgm cv",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "cgm hbgi",
      "value": 4
    },
    {
      "source": "hip circumference",
      "target": "cgm above 180",
      "value": 4
    },
    {
      "source": "bt glucose float value",
      "target": "cgm auc",
      "value": 5
    },
    {
      "source": "bt glucose float value",
      "target": "cgm cogi",
      "value": 5
    },
    {
      "source": "bt glucose float value",
      "target": "cgm conga",
      "value": 5
    },
    {
      "source": "bt glucose float value",
      "target": "cgm cv",
      "value": 5
    },
    {
      "source": "bt glucose float value",
      "target": "cgm above 180",
      "value": 5
    },
    {
      "source": "bt glucose float value",
      "target": "cgm below 70",
      "value": 5
    },
    {
      "source": "bt glucose float value",
      "target": "cgm in range 70 180",
      "value": 5
    },
    {
      "source": "bt hba1c float value",
      "target": "cgm auc",
      "value": 5
    },
    {
      "source": "bt hba1c float value",
      "target": "cgm cogi",
      "value": 5
    },
    {
      "source": "bt hba1c float value",
      "target": "cgm conga",
      "value": 5
    },
    {
      "source": "bt hba1c float value",
      "target": "cgm cv",
      "value": 5
    },
    {
      "source": "bt hba1c float value",
      "target": "cgm above 180",
      "value": 5
    },
    {
      "source": "bt hba1c float value",
      "target": "cgm below 70",
      "value": 5
    },
    {
      "source": "bt hba1c float value",
      "target": "cgm in range 70 180",
      "value": 5
    },
    {
      "source": "bt total cholesterol float value",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "bt total cholesterol float value",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "bt hdl cholesterol float value",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "bt hdl cholesterol float value",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "ng total cholesterol",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "ng total cholesterol",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "ng ldl cholesterol",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "ng ldl cholesterol",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "ng hdl cholesterol",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "ng hdl cholesterol",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "ng triglycerides",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "ng triglycerides",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "ng apolipoprotein b",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "ng apolipoprotein b",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "ng ldl particle size",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "ng ldl particle size",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "ng vldl particle conc",
      "target": "imt left",
      "value": 4
    },
    {
      "source": "ng vldl particle conc",
      "target": "imt right",
      "value": 4
    },
    {
      "source": "ng triglycerides",
      "target": "lying blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "lying blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "sitting blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "sitting blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "sitting second blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "sitting second blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "standing one min blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "standing one min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "standing three min blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng triglycerides",
      "target": "standing three min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "lying blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "lying blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "sitting blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "sitting blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "sitting second blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "sitting second blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "standing one min blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "standing one min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "standing three min blood pressure systolic",
      "value": 3
    },
    {
      "source": "ng vldl particle conc",
      "target": "standing three min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt alt float value",
      "target": "liver elasticity 2D SWE",
      "value": 5
    },
    {
      "source": "bt alt float value",
      "target": "liver viscosity vi plus",
      "value": 5
    },
    {
      "source": "bt alt float value",
      "target": "liver attenuation index att plus",
      "value": 5
    },
    {
      "source": "bt alt float value",
      "target": "liver speed of sound ssp plus",
      "value": 5
    },
    {
      "source": "bt ast float value",
      "target": "liver elasticity 2D SWE",
      "value": 5
    },
    {
      "source": "bt ast float value",
      "target": "liver viscosity vi plus",
      "value": 5
    },
    {
      "source": "bt ast float value",
      "target": "liver attenuation index att plus",
      "value": 5
    },
    {
      "source": "bt ast float value",
      "target": "liver speed of sound ssp plus",
      "value": 5
    },
    {
      "source": "bt ggt float value",
      "target": "liver elasticity 2D SWE",
      "value": 5
    },
    {
      "source": "bt ggt float value",
      "target": "liver viscosity vi plus",
      "value": 5
    },
    {
      "source": "bt ggt float value",
      "target": "liver attenuation index att plus",
      "value": 5
    },
    {
      "source": "bt ggt float value",
      "target": "liver speed of sound ssp plus",
      "value": 5
    },
    {
      "source": "bt alkaline phosphatase float value",
      "target": "liver elasticity 2D SWE",
      "value": 5
    },
    {
      "source": "bt alkaline phosphatase float value",
      "target": "liver viscosity vi plus",
      "value": 5
    },
    {
      "source": "bt alkaline phosphatase float value",
      "target": "liver attenuation index att plus",
      "value": 5
    },
    {
      "source": "bt alkaline phosphatase float value",
      "target": "liver speed of sound ssp plus",
      "value": 5
    },
    {
      "source": "bt total bilirubin float value",
      "target": "liver elasticity 2D SWE",
      "value": 5
    },
    {
      "source": "bt total bilirubin float value",
      "target": "liver viscosity vi plus",
      "value": 5
    },
    {
      "source": "bt total bilirubin float value",
      "target": "liver attenuation index att plus",
      "value": 5
    },
    {
      "source": "bt total bilirubin float value",
      "target": "liver speed of sound ssp plus",
      "value": 5
    },
    {
      "source": "bt albumin float value",
      "target": "liver elasticity 2D SWE",
      "value": 5
    },
    {
      "source": "bt albumin float value",
      "target": "liver viscosity vi plus",
      "value": 5
    },
    {
      "source": "bt albumin float value",
      "target": "liver attenuation index att plus",
      "value": 5
    },
    {
      "source": "bt albumin float value",
      "target": "liver speed of sound ssp plus",
      "value": 5
    },
    {
      "source": "ahi",
      "target": "lying blood pressure systolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "lying blood pressure diastolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "sitting blood pressure systolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "sitting blood pressure diastolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "sitting second blood pressure systolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "sitting second blood pressure diastolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "standing one min blood pressure systolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "standing one min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "standing three min blood pressure systolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "standing three min blood pressure diastolic",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "bt glucose float value",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "bt hba1c float value",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "cgm cv",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "cgm above 180",
      "value": 4
    },
    {
      "source": "ahi",
      "target": "cgm below 70",
      "value": 4
    },
    {
      "source": "bt sodium float value",
      "target": "lying blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "lying blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "sitting blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "sitting blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "sitting second blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "sitting second blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "standing one min blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "standing one min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "standing three min blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt sodium float value",
      "target": "standing three min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "lying blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "lying blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "sitting blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "sitting blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "sitting second blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "sitting second blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "standing one min blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "standing one min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "standing three min blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt creatinine float value",
      "target": "standing three min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "lying blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "lying blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "sitting blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "sitting blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "sitting second blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "sitting second blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "standing one min blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "standing one min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "standing three min blood pressure systolic",
      "value": 3
    },
    {
      "source": "bt calcium float value",
      "target": "standing three min blood pressure diastolic",
      "value": 3
    },
    {
      "source": "bt hemoglobin float value",
      "target": "ahi",
      "value": 2
    },
    {
      "source": "bt hematocrit float value",
      "target": "ahi",
      "value": 2
    },
    {
      "source": "bt rbc float value",
      "target": "ahi",
      "value": 2
    },
    {
      "source": "bt rheumatoid factor float value",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "bt rheumatoid factor float value",
      "target": "imt right",
      "value": 2
    },
    {
      "source": "bt rheumatoid factor float value",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "bt rheumatoid factor float value",
      "target": "liver viscosity vi plus",
      "value": 2
    },
    {
      "source": "bt rheumatoid factor float value",
      "target": "liver attenuation index att plus",
      "value": 2
    },
    {
      "source": "bt rheumatoid factor float value",
      "target": "liver speed of sound ssp plus",
      "value": 2
    },
    {
      "source": "bt rdw float value",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "bt rdw float value",
      "target": "imt right",
      "value": 2
    },
    {
      "source": "bt rdw float value",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "bt rdw float value",
      "target": "liver viscosity vi plus",
      "value": 2
    },
    {
      "source": "bt rdw float value",
      "target": "liver attenuation index att plus",
      "value": 2
    },
    {
      "source": "bt rdw float value",
      "target": "liver speed of sound ssp plus",
      "value": 2
    },
    {
      "source": "bt ferritin float value",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "bt ferritin float value",
      "target": "imt right",
      "value": 2
    },
    {
      "source": "bt ferritin float value",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "bt ferritin float value",
      "target": "liver viscosity vi plus",
      "value": 2
    },
    {
      "source": "bt ferritin float value",
      "target": "liver attenuation index att plus",
      "value": 2
    },
    {
      "source": "bt ferritin float value",
      "target": "liver speed of sound ssp plus",
      "value": 2
    },
    {
      "source": "bt total protein float value",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "bt total protein float value",
      "target": "imt right",
      "value": 2
    },
    {
      "source": "bt total protein float value",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "bt total protein float value",
      "target": "liver viscosity vi plus",
      "value": 2
    },
    {
      "source": "bt total protein float value",
      "target": "liver attenuation index att plus",
      "value": 2
    },
    {
      "source": "bt total protein float value",
      "target": "liver speed of sound ssp plus",
      "value": 2
    },
    {
      "source": "bt albumin float value",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "bt albumin float value",
      "target": "imt right",
      "value": 2
    },
    {
      "source": "bt albumin float value",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "bt albumin float value",
      "target": "liver viscosity vi plus",
      "value": 2
    },
    {
      "source": "bt albumin float value",
      "target": "liver attenuation index att plus",
      "value": 2
    },
    {
      "source": "bt albumin float value",
      "target": "liver speed of sound ssp plus",
      "value": 2
    },
    {
      "source": "ng omega 3 pct",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "ng omega 3 pct",
      "target": "liver viscosity vi plus",
      "value": 2
    },
    {
      "source": "ng omega 3 pct",
      "target": "liver attenuation index att plus",
      "value": 2
    },
    {
      "source": "ng omega 3 pct",
      "target": "liver speed of sound ssp plus",
      "value": 2
    },
    {
      "source": "ng omega 3 pct",
      "target": "bt hba1c float value",
      "value": 2
    },
    {
      "source": "ng omega 3 pct",
      "target": "cgm cv",
      "value": 2
    },
    {
      "source": "ng omega 6 pct",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "ng omega 6 pct",
      "target": "liver viscosity vi plus",
      "value": 2
    },
    {
      "source": "ng omega 6 pct",
      "target": "liver attenuation index att plus",
      "value": 2
    },
    {
      "source": "ng omega 6 pct",
      "target": "liver speed of sound ssp plus",
      "value": 2
    },
    {
      "source": "ng omega 6 pct",
      "target": "bt hba1c float value",
      "value": 2
    },
    {
      "source": "ng omega 6 pct",
      "target": "cgm cv",
      "value": 2
    },
    {
      "source": "ng polyunsaturated fatty acids pct",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "ng polyunsaturated fatty acids pct",
      "target": "liver viscosity vi plus",
      "value": 2
    },
    {
      "source": "ng polyunsaturated fatty acids pct",
      "target": "liver attenuation index att plus",
      "value": 2
    },
    {
      "source": "ng polyunsaturated fatty acids pct",
      "target": "liver speed of sound ssp plus",
      "value": 2
    },
    {
      "source": "ng polyunsaturated fatty acids pct",
      "target": "bt hba1c float value",
      "value": 2
    },
    {
      "source": "ng polyunsaturated fatty acids pct",
      "target": "cgm cv",
      "value": 2
    },
    {
      "source": "ng branched chain amino acids",
      "target": "bt glucose float value",
      "value": 2
    },
    {
      "source": "ng branched chain amino acids",
      "target": "bt hba1c float value",
      "value": 2
    },
    {
      "source": "ng branched chain amino acids",
      "target": "cgm cv",
      "value": 2
    },
    {
      "source": "ng branched chain amino acids",
      "target": "cgm above 180",
      "value": 2
    },
    {
      "source": "ng glutamine",
      "target": "bt glucose float value",
      "value": 2
    },
    {
      "source": "ng glutamine",
      "target": "bt hba1c float value",
      "value": 2
    },
    {
      "source": "ng glutamine",
      "target": "cgm cv",
      "value": 2
    },
    {
      "source": "ng glutamine",
      "target": "cgm above 180",
      "value": 2
    },
    {
      "source": "ng ketone bodies",
      "target": "bt glucose float value",
      "value": 2
    },
    {
      "source": "ng ketone bodies",
      "target": "bt hba1c float value",
      "value": 2
    },
    {
      "source": "ng ketone bodies",
      "target": "cgm cv",
      "value": 2
    },
    {
      "source": "ng ketone bodies",
      "target": "cgm above 180",
      "value": 2
    },
    {
      "source": "ng citrate",
      "target": "bt glucose float value",
      "value": 2
    },
    {
      "source": "ng citrate",
      "target": "bt hba1c float value",
      "value": 2
    },
    {
      "source": "ng citrate",
      "target": "cgm cv",
      "value": 2
    },
    {
      "source": "ng citrate",
      "target": "cgm above 180",
      "value": 2
    },
    {
      "source": "lying blood pressure systolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "lying blood pressure systolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "lying blood pressure diastolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "lying blood pressure diastolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "sitting blood pressure systolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "sitting blood pressure systolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "sitting blood pressure diastolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "sitting blood pressure diastolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "sitting second blood pressure systolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "sitting second blood pressure systolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "sitting second blood pressure diastolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "sitting second blood pressure diastolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "standing one min blood pressure systolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "standing one min blood pressure systolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "standing one min blood pressure diastolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "standing one min blood pressure diastolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "standing three min blood pressure systolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "standing three min blood pressure systolic",
      "target": "imt right",
      "value": 5
    },
    {
      "source": "standing three min blood pressure diastolic",
      "target": "imt left",
      "value": 5
    },
    {
      "source": "standing three min blood pressure diastolic",
      "target": "imt right",
      "value": 5
    },

    {
      "source": "weight",
      "target": "height",
      "value": 2
    },
    {
      "source": "bmi",
      "target": "height",
      "value": 2
    },
    {
      "source": "waist circumference",
      "target": "height",
      "value": 2
    },
    {
      "source": "hip circumference",
      "target": "height",
      "value": 2
    },
    {
      "source": "neck circumference",
      "target": "height",
      "value": 2
    },
    {
      "source": "waist to hip ratio",
      "target": "height",
      "value": 2
    },
    {
      "source": "lying blood pressure diastolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "lying blood pressure pulse rate",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "sitting blood pressure systolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "sitting blood pressure diastolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "sitting blood pressure pulse rate",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "sitting second blood pressure systolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "sitting second blood pressure diastolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "sitting second blood pressure pulse rate",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "standing one min blood pressure systolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "standing one min blood pressure diastolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "standing one min blood pressure pulse rate",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "standing three min blood pressure systolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "standing three min blood pressure diastolic",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "standing three min blood pressure pulse rate",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "blood pressure hand",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "dizziness",
      "target": "lying blood pressure systolic",
      "value": 2
    },
    {
      "source": "bt alkaline phosphatase float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt alt float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt ast float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt basophils % float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt basophils abs float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt calcium float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt creatinine float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt direct bilirubin float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt eosinophils % float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt eosinophils abs float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt estradiol float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt ferritin float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt ggt float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt glucose float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt hba1c float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt hdl cholesterol float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt hematocrit float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt hemoglobin float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt rbc float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt rdw float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt rheumatoid factor float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt sodium float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt total bilirubin float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt total cholesterol float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "bt total protein float value",
      "target": "bt albumin float value",
      "value": 2
    },
    {
      "source": "cgm 3rd quartile",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm above 140",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm above 180",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm above 250",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm below 54",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm below 70",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm in range 63 140",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm in range 70 180",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm adrr",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm auc",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm cogi",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm conga",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm cv",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm cv measures mean",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm gvp",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm hbgi",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm hyper index",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm daily cogi",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm daily gvp",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "cgm daily hbgi",
      "target": "cgm 1st quartile",
      "value": 2
    },
    {
      "source": "imt right",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "imt window width left",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "imt window width right",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "imt fit left",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "imt fit right",
      "target": "imt left",
      "value": 2
    },
    {
      "source": "liver viscosity vi plus",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "liver attenuation index att plus",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "liver speed of sound ssp plus",
      "target": "liver elasticity 2D SWE",
      "value": 2
    },
    {
      "source": "ng ldl cholesterol",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng hdl cholesterol",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng triglycerides",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng apolipoprotein a1",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng apolipoprotein b",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng ldl particle size",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng vldl particle conc",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng hdl particle conc",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng omega 3 pct",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng omega 6 pct",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng polyunsaturated fatty acids pct",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng branched chain amino acids",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng glutamine",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng citrate",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "ng ketone bodies",
      "target": "ng total cholesterol",
      "value": 2
    },
    {
      "source": "height",
      "target": "lying blood pressure systolic",
      "value": 1
    },
    {
      "source": "lying blood pressure systolic",
      "target": "bt albumin float value",
      "value": 1
    },
    {
      "source": "bt albumin float value",
      "target": "cgm 1st quartile",
      "value": 1
    },
    {
      "source": "cgm 1st quartile",
      "target": "ahi",
      "value": 1
    },
    {
      "source": "ahi",
      "target": "imt left",
      "value": 1
    },
    {
      "source": "imt left",
      "target": "liver elasticity 2D SWE",
      "value": 1
    },
    {
      "source": "liver elasticity 2D SWE",
      "target": "ng total cholesterol",
      "value": 1
    }
  ]
}